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ABSTRACT 
 Idiopathic pulmonary fibrosis (IPF) is the most common and the most aggressive 
fibrosing interstitial lung disease (ILD). Despite recent promising clinical trials, IPF 
remains incurable and largely untreatable. Genetic studies have identified several risk 
loci for both sporadic and familial forms of IPF. A single variant upstream of MUC5B is 
predicted to account for more than 30% of all IPF risk. This variant, rs35705950, is 
associated with expression of MUC5B in healthy lung tissue. However, the mechanism 
underlying the relationship between rs35705950 and MUC5B expression remains 
unclear.  
 The first goal of my thesis research was to determine whether rs35705950 is 
also a risk factor for other forms of ILD. Genomic DNA from individuals with IPF, HP, 
COPD, iNSIP, and RB-ILD was obtained and genotyped for the common MUC5B 
promoter variant. In these populations the risk allele was associated with IPF and iNSIP 
which suggested a potential shared disease mechanism. Additionally, I showed that in 
the IPF and control populations rs35705950 is associated with lung MUC5B expression.  
 The second goal of my thesis research was to investigate MUC5B promoter DNA 
methylation which has previously been shown to play a role in MUC5B expression. 
Methylation analysis of the 4KB region upstream of MUC5B identified two differentially 
methylated regions (DMRs) associated with IPF, one DMR associated with MUC5B 
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expression, and one DMR associated with rs35705950. The IPF, MUC5B expression, and 
rs35705950 associated DMRs are all differentially methylated at a cluster of 11 CpG 
motifs. overlapping DMR, including the motif disrupted by rs35705950. These findings 
suggest that DNA methylation may play a role in MUC5B gene regulation and IPF risk.  
 Next, I used cross species analysis to identify highly conserved domains within 
the overlapping DMR. Evolutionary conservation indicated selective pressures to 
maintain sequences overtime and suggests biological importance. The overlapping DMR 
contains a highly conserved binding motif for FOXA2, a transcription factor. Further 
analysis using ChIP-qPCR, reporter constructs, and siRNA, established a role for FOXA2 
in regulation of MUC5B expression in lung tissue. Additionally, siRNA knock down 
identified 3 other transcription factors which are associated with MUC5B expression; 
STAT3, HOXA9 and ZBTB7A.  These transcriptional regulators provide insight into 
possible therapeutic intervention for MUC5B dysregulation and IPF.  
The form and content of this abstract are approved. I recommend its publication. 
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GENETICS AND EPIGENETICS OF IDIOPATHIC PULMONARY FIBROSIS* 
Idiopathic Pulmonary Fibrosis 
Interstitial lung diseases (ILDs) are a large group of inflammatory and fibrotic 
lung diseases with diverse phenotypes and pathologies. The most common fibrosing 
ILD (fILD) is idiopathic pulmonary fibrosis (IPF)[1], a chronic fibrotic lung disease with 
an unpredictable progression and aggressive nature [2-7]. IPF is characterized 
pathologically by usual interstitial pneumonia (UIP) patterns and honeycomb cyst 
formations on high resolution computer tomography (HRCT) and presence of 
fibroblastic foci and microscopic honeycomb cysts on histology [8-11]. Although the 
American Thoracic Society and other international respiratory agencies have agreed 
upon criteria for the diagnosis of IPF, diagnoses can still be unclear and variable among 
and between clinicians, radiologists and pathologists. Additionally, differentiating 
between ILDs is further complicated by significant overlap in clinical phenotypes and 
the patchy co-occurrence of multiple ILDs in a single individual [10, 11].  
Idiopathic pulmonary fibrosis is a late-age-of-onset lung disease with a median 
survival of only 2-5 years.  The characteristic fibrosis in IPF is progressive and leads to 
loss of lung function, dyspnea, hypoxemia, and ultimately respiratory failure and death. 
The prevalence of IPF is estimated at 63 individuals per 100,000 in the United States 
[12], with the prevalence and mortality increasing as our population ages [7]. 
Treatment options for IPF are limited to two recently approved drugs with modest 
effect on disease progression and significant side effects [13, 14].  




The pathogenic paradigm has shifted from the concept that IPF is a result of 
chronic inflammation [16] to the idea that IPF results from excessive, sequential injury 
and/or aberrant wound healing of the alveolar epithelium [17]. Additionally, it is now 
thought that the distal airway epithelium contributes to disease development [18-20]. 
The disease process underlying IPF is likely heterogeneous with many different cell 
types [21-23] and molecular processes involved [18, 19, 24-38]. Irrespective of the 
specific pathways that lead to fibrosis, the end result is usual interstitial pneumonia, a 
histological pattern of heterogeneous, subpleural regions of fibrotic and remodeled lung 
[39].  
Gene expression profiling studies have demonstrated that extensive 
transcriptional changes are present in the lung parenchyma of individuals with IPF [40-
46]. Gene expression changes are dramatic and have consistently identified genes 
associated with extracellular matrix (ECM) formation, degradation, signaling, smooth 
muscle markers, growth factors, developmental pathways, and genes encoding 
immunoglobulins, complement, chemokines, and other host defense/innate immune 
genes. We also recently identified two molecular subtypes of IPF based on a strong gene 
expression signature of cilium-associated genes [22]. Interestingly, expression of 
MUC5B, the strongest and most replicated genetic risk factor for IPF [19, 47-52], is 
highly correlated to expression of cilium genes. Furthermore, MUC5B expression is also 
associated with expression of MMP7, an extracellular matrix gene that has emerged as a 
significant expression biomarker for IPF [41, 44, 53] and was recently shown to play a 
role in attenuating ciliated cell differentiation during wound repair [54]. While gene 
expression studies in aggregate have been successful in identifying molecular processes 
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that are dysregulated in IPF lung, we know much less about how expression of these 
genes is regulated at the transcriptional, post-transcriptional, and post-translational 
levels. 
Genetics of IPF 
Familial clustering of IPF has been observed for decades [55, 56]suggesting a 
strong genetic component. Genome-wide association study (GWAS) and linkage 
analyses in sporadic and familial pulmonary fibrosis respectively have identified a 
network of risk genes associated with telomere function, cell-cell adhesion, surfactant, 
mucin composition, and immune function (summarized in [57, 58]). GWAS analyses 
have predicted that common genetic variants can explain more than 30% of overall IPF 
risk while rare variants can explain an additional 15-20% [49, 57]. Additionally, our lab 
has recently estimated that ~30% of IPF risk can be explained by the common MUC5B 
promoter polymorphism alone. Together these data suggest that as much as 80% of all 
IPF risk can now be explained by the known genetic variants. 
 Telomere 
Genetic variants in telomere associated genes are found in 8-15% of individuals 
with IPF. These mutations are associated with more severe phenotypes and earlier 
onset. Additionally, IPF patients with telomere associated mutations commonly have 
comorbidities affecting multiple organ systems [59]. Mutations in several telomere 
associated genes have been linked with IPF including, hTR, TERT, TERC, TINF2, RTEL1, 
and DKC1 [33-35, 60-62]. The primary effect of these mutations is telomere shortening 
which leads to a premature aging phenotype [63]. Notably, short telomeres are a 




Newly identified mutations in cell-cell adhesion and epithelial structure genes 
support the new paradigm for IPF development which focuses on repetitive damage 
and aberrant wound healing. GWAS has identified variants in DSP, a major component 
of the desmosome, and DPP9 which contributes to cytoskeleton maintenance. Both of 
these genes are also known to be upregulated in IPF [49] and their dysregulation likely 
impairs barrier function [66]. 
Surfactant 
 Surfactant lipids are required for maintenance of surface tension at the lung 
epithelium for proper gas exchange and the surfactant proteins contribute to innate 
immunity within the lungs [67, 68]. Premature infants with underdeveloped lungs often 
become hypoxic and die due to a high surface tension at the epithelial layer due to the 
under-expression of surfactant lipids[69, 70]. In IPF, mutations occur in the surfactant 
genes SFTPC [71-74], SFTPA2 [75], and ABCA3 [76]. The IPF variants in these genes lead 
to misfolded and shortened proteins and aberrant expression [77]. It is estimated that 
15-20 % of cases of IPF have mutations in surfactant related genes [77].   
Mucins 
Mucins play essential roles in the lung including barrier functions, lung 
homeostasis and immune regulation [78-81]. The common MUC5B promoter variant 
rs35705950 is the most significantly associated and most reproduced genetic risk 
factor for IPF [19, 47-49, 51, 76, 82-86]. We estimate that 30% of IPF risk (genetic or 
otherwise) can be attributed to this single variant (unpublished data). The common 
MUC5B variant is associated with increased expression of MUC5B in non-fibrotic 
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control lung and may lead to IPF through disruption of mechanical clearance, immune 
cell recruitment or lung homeostasis [19]. 
Epigenetics of IPF 
As much as 80% of the human genome is predicted to be regulatory. These 
regions include promoters, enhancers, insulators and other regulatory elements that 
are labeled by epigenetic marks [87, 88]. Almost every cell in the human body has the 
same DNA sequence: however, there is a wide range of different expression profiles. 
This differential gene expression is orchestrated by the epigenome [89]. In addition to 
the genetically determined epigenetic patterns, environmental exposures can also 
translate into epigenetic changes. Epigenetic alterations can be tissue, cell type, and 
gene specific and contribute to disease phenotypes [90]. 
Epigenetics are emerging as key mechanisms that mediate the effects of both 
genetics and the environment on gene expression and disease [91, 92]. Although 
epigenetics is a broad term referring to all of the non-base-pair changes to the genome, 
most studies, including my work, focus on DNA methylation and histone modifications 
because of the abundance of information they provide and the ease by which they are 
assayed.  
DNA Methylation 
DNA methylation typically occurs at cytosine residues in CpG dinucleotides (5’ 
cytosine-phosphate-guanine 3’). Methylated cytosine residues (5’-methylcytosine) are 
prone to mutagenesis to thymine. This mutagenesis has led to a lower than expected 
frequency of CpG nucleotides throughout the human genome. However, there are areas 
of densely clustered CpGs called CpG islands [93] which are found in more than 60-70% 
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of gene promoters [94, 95]. In the majority of promoter associated CpG islands, DNA 
methylation and transcription levels are inversely correlated, a relationship that is 
explained by DNA methylation inhibiting the binding of transcriptional activators [96-
99]. Less commonly, DNA methylation and gene expression are positively correlated in 
cases where binding of transcription factors is enhanced by methylation such as in C/EBPα [100, 101] and also in the case of repressor binding being inhibited by DNA 
methylation such as with CTCF [102]. More recently it has been demonstrated that 
methylation of less CpG dense regions near islands (‘CpG island shores’)[103, 104] and 
within gene bodies[105, 106] is also important in regulation of gene transcription as 
well as alternative splicing. Although CpG methylation is the most common form of DNA 
methylation, non-CpG methylation occurs at high frequency in embryonic stem cells 
[107]. Additionally, there are at least 2 types of methylation, 5’ methyl-cytosine and 5-
hydroxymethylcytosine, the latter of which may be a mark of demethylation[108]. 
Notably, most methods for methylation detection do not differentiate between these 
types of methylation.  
DNA methyltransferases are enzymes responsible for establishment 
(DNMT3A/B) and maintenance (DNMT1) of DNA methylation while the TET family of 
enzymes actively demethylate DNA though the 5-hydoxymethylcytosine intermediate 
[108]. 
Histone Modifications 
Histones are proteins that enable DNA molecules to be tightly packaged into 
chromosomes inside the cell nucleus. While a number of different histone modifications 
exist, acetylation and methylation are the most common modifications of histone tails. 
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These modifications occur at specific sites and residues, and control gene expression by 
regulating DNA accessibility to RNA polymerase II and transcription factors. Histone 
acetyltransferases (HATs) acetylate histone tails, histone deacetylases (HDACs) remove 
acetyl groups from histone tails, and bromodomain (Brd) proteins are chromatin 
readers that recognize and bind acetylated histones and play a key role in transmission 
of epigenetic memory across cell divisions and transcription regulation [109, 110]. 
Similarly, histone methyltransferases (HMTs) add the methyl groups to histone tails 
while histone demethylases (HDMs) remove them [109, 110]. Histone modifications can 
be used to fine map regulatory activity. Acetylation of lysine 27 on the histone H3 
(H3K27ac) is, for example, one of the most informative single histone modifications. It 
is known to mark active enhancers and promoters[111]. H3K27 trimethylation on the 
other hand is a marker of repression[112].  
Methylation Changes within the IPF Genetic Loci 
Recent work in the field of genetics of IPF has made it clear that there is a strong 
genetic component to this disease [49]. We intersected the 2,130 IPF-associated DMRs 
with recently identified loci from the two published genome-wide association studies in 
IPF [49, 50] and identified methylation changes in genes within 5 of these loci [113].  Of 
special interest are genes that are differentially expressed in IPF lung and whose 
expression may be regulated by both genetic variants and DNA methylation. As more 
genetic discoveries are made and the loci that have already been associated with IPF 




Toll interacting protein (TOLLIP), a gene involved in innate immunity and 
inflammation, has emerged as a potential genetic candidate in addition to MUC5B on 
chromosome 11 [50], is 1.6 fold downregulated. We identified two intronic DMRs in 
TOLLIP that are ~11% hypermethylated in IPF compared to controls. 
Hypermethylation of TOLLIP has recently been observed in synovial fibroblasts of 
patients with rheumatoid arthritis [114].  
DSP  
Desmoplakin (DSP), a key component of tight junctions, is located in one of the 
most precisely mapped IPF-associated GWAS loci [49], is 1.8 fold upregulated, and has 
two hypomethylated intronic DMRs with one of the DMRs in the first intron. DSP 
expression is regulated by DNA methylation in non-small cell lung cancer [115]. 
MUC5B 
The strongest genetic risk factor for IPF is associated with MUC5B whose 
expression appears to be regulated at least in part by the IPF-associated promoter 
polymorphism rs35705950 [19, 116]. This MUC5B promoter variant is associated with 
a 34.1-fold increase in MUC5B expression in lung tissue among unaffected subjects and 
a 5.3-fold increase among IPF patients. Additionally, IPF patients express 14.1-fold 
more MUC5B than unaffected controls. While our genomic methylation study did not 
identify DMRs near the MUC5B gene, there is reasonable evidence for the potential role 
of DNA methylation in regulation of MUC5B expression. The variant is approximately 
3kb upstream of the MUC5B transcriptional start site, in an area of open chromatin, a 
dense region of ChIP-seq hits, in a highly conserved genomic region and within a CpG 
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island, strongly suggesting that this region is important for gene regulation. DNase 
hypersensitivity assays indicate areas of open transcriptionally active chromatin [117]. 
In the ENCODE project, 19 of the 125 analyzed cell lines, including the lung epithelial 
carcinoma cell line A549, have open chromatin in the chromosomal region overlapping 
the MUC5B promoter polymorphism (Chr11:1241201-1241350 for A549) [117]. Areas 
of open chromatin are often associated with binding of enhancer, silencer and other 
regulator elements [87, 117]. Large scale ChIP-seq analysis, also part of the ENCODE 
project, has demonstrated binding of at least 20 transcription factors to the A549 
specific DNase hypersensitivity region described above, with 18 transcription factors 
predicted to bind in the region overlapping the common polymorphism [118-120].  
Moreover, the promoter polymorphism is located within a ~200bp CpG island 
motif (Chr11:1241162-1241364), which is of particular interest given that the variant 
(G to T transversion) allele at rs35705950 disrupts a CpG motif and therefore directly 
affects methylability of the adjacent cytosine. Although rs35705950 provides a very 
pointed example of a potential epigenetic regulator, more global changes in DNA 
methylation have also been associated with MUC5B expression. Vincent et al. previously 
showed that in vitro exposure to 5-azacytidine, a global DNA demethylating agent, can 
alter MUC5B expression [121, 122]. We also know that this region of chromosome 11 
becomes differentially methylated in some forms of cancer [123]. Understanding the 
contributions of DNA methylation and rs35705950 to the regulation of MUC5B is an 
important step in understanding IPF pathogenesis. 
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Treatment of IPF 
Perhaps due to the insidious nature of IPF, the nondescript early clinical 
phenotypes, or the unclear pathogenesis, a diagnosis of IPF is typically made late in 
disease progression with an average survival of 2 to 5 years [124-129]. As IPF 
progresses, the clinical phenotype becomes more severe and quality of life rapidly 
diminishes [124-129]. Although currently the only cure for IPF is lung transplantation 
[130], recent clinical trials have identified the first successful treatment options for IPF, 
Pirfenidone and Nintedanib. Pirfenidone is thought to affect disease progression 
through inhibition of TGF-β leading to decreased deposition of collagen and 
extracellular matrix within the lung [131]. Similarly, Nintedanib is a triple kinase 
inhibitor thought to downregulate mitogenic factors[132]. Although both treatments 
are viable options for patients suffering from IPF, they do not stop the progression of 
IPF and their long term effects on disease progression and lung homeostasis are still 
unknown[133]. Additionally, Pirfenidone and Nintedanib treatments come with an 
array of side effects including nausea, diarrhea, and fatigue, which are reported to lower 
quality of life and in some cases require cessation of treatment [134-137]. Although 
Pirfenidone and Nintedanib have given hope to the IPF community, as we begin to 
better understand the causes and pathogenesis of IPF, more effective and finely 
targeted treatment options will be possible.  
Identification of key epigenetic marks that are shaped by the genetics and 
environment and influence transcription of specific genes will not only help us 
understand the etiology and heterogeneity of IPF but will also empower us to develop 
biologically driven therapeutics and biomarkers for secondary prevention of this 
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disease. DNA methylation changes have been shown to drive tumor formation and 
malignant progression [138], and as such have established basic mechanisms for 
disease pathogenesis, as well as targets for intervention in cancer. DNMT inhibitors 
have been approved for the treatment of myelodysplastic syndrome [139, 140] and are 
in clinical trials for treatment of solid tumors [141, 142]. While currently available 
DNMT inhibitors lack specificity for gene(s) of interest, locus-specific therapies are 
currently being developed using genome editing technologies [138, 143] or taking 
advantage of recently discovered DNMT1-interacting noncoding RNAs [144]. 
Additionally, current FDA-approved and in development histone mark modifying drugs 
are effective in targeting specific gene loci and pathways [109, 145] and for treating 
diseases such as lung cancer [146]. As a proof of principle for IPF, profibrotic 
phenotypes have been reversed in primary fibroblasts and the bleomycin mouse model 
by the Brd4 inhibitor JQ1 [147] as well as HDAC inhibitors Spiruchostatin A (SpA) [148] 
and suberoylanilide hydroxamic acid (SAHA) [149].  
MUC5B’s Role in the Lung 
MUC5B (mucin 5B) is a secreted mucin found throughout the body and is the 
predominant mucin expressed in the airways [150]. MUC5B is secreted primarily by 
surface secretory cells and submucosal glands and is a major component of lung mucus. 
The main roles of MUC5B in the airways are barrier functions, mucociliary clearance, 
lung homeostasis, and immune regulation [78-81].  
When dysregulated, MUC5B is associated with a variety of lung diseases 
including diffuse panbronchiolitis [151], coal workers pneumoconiosis[152], asthma 
[153], and IPF[19]. Mouse Muc5b KO models show a 90% decrease in mucociliary 
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clearance as well as increased airway inflammation and eventually death by 
spontaneous infection [78, 154, 155]. Although different exposures such as NRG1beta1 
[156], fibronectin and laminin [157] have been shown to change the expression of 
MUC5B the regulatory mechanisms are still poorly understood.   
Aims 
 Although it has thoroughly been established as a risk factor for IPF, the 
mechanisms underlying the association between IPF and rs35705950 are poorly 
understood. The main goal of my thesis was to clarify the role of rs35705950 in the 
development of IPF and identify key regulatory mechanisms for expression of MUC5B 
in the lung. To do this, I had 4 main aims: 
 
Determine if rs35705950 is a unique risk factor for IPF or a general risk factor for ILD: 
The prevalence of the IPF risk allele (T) at rs35705950 was assayed in non-fibrotic 
controls, IPF, COPD, HP, iNSIP, and RB-ILD.      
 
Investigate the association between rs35705950 and MUC5B expression in Control and 
IPF lung: The relationship between rs35705950 and MUC5B expression in non-fibrotic 
control and IPF lung was assayed. 
 
Examine MUC5B promoter methylation patterns: The DNA methylation state of the 
region directly 5’ of the MUC5B TSS to 4KB upstream was assayed. Association between 




Determine regulatory mechanisms for MUC5B expression: The critical MUC5B enhancer 
was defined by deep-conservation, and site directed mutagenesis of a reporter complex.  





RS35705950 AND RISK OF INTERSTITIAL LUNG DISEASE 
Introduction 
 Interstitial lung diseases (ILDs) are a group of conditions either of known or 
unknown origins with a common set of characteristics including shortness of breath, 
cough, diffuse infiltrates and decreased pulmonary function scores [158, 159]. Although 
there is significant overlap between the phenotypes of different ILDs, the pathologies, 
responses to treatment, and prognoses vary drastically. For example, the average 
survival for acute hypersensitivity pneumonitis (HP) is about 22 years [160] while the 
average survival in IPF is only 2-5 years [124-128]. Additionally, some ILDs may occur 
independently while others occur as part of a syndrome with a wide variety of 
comorbidities. For example, both sarcoidosis and rheumatoid arthritis are associated 
with increased risk of interstitial lung disease [161, 162]. 
Obviously, differentiating between ILDs is important; however, this can be a 
challenging process, especially early on in disease development when clinical 
phenotypes can be subtle. Although the American Thoracic Society routinely releases 
updated guidelines for the diagnosis of specific ILDs, they emphasize the fact that 
additional biomarkers are necessary for the differentiation and identification of ILDs 
[10, 11, 39]. Genetic studies such as genome-wide association studies (GWAS) and 
linkage analyses have begun to untangle the causes of ILDs and will also likely aid in the 
reclassification of diseases, alter the prescribed course of treatment, and lead to novel 





In 2011, Seibold et al. identified a common MUC5B promoter polymorphism, 
rs35705950, which is associated with both familial and sporadic forms of pulmonary 
fibrosis [19]. Since its identification, the association between this single nucleotide 
polymorphism (SNP) and IPF has been replicated in 11 independent studies [48, 49, 51, 
52, 76, 82, 84-86, 163, 164]. This association is maintained in all tested populations that 
had greater than a 1% prevalence of the minor allele including Mexican [84], Chinese 
[85] and Japanese cohorts [86] but not in a Korean population where the allele 
frequency was less than 1% [84]. The MUC5B promoter variant is also associated with 
phenotypic variability in IPF including prevalence of ground glass opacities, subpleural 
axial distribution of fibrosis, and survival [82, 165-171]. The MUC5B promoter 
polymorphism is also associated with increased prevalence of interstitial abnormalities 
in asymptomatic controls [172] suggesting the utility of rs35705950 in the early 
detection of IPF. Alternatively, this association in asymptomatic controls could suggest 
that the polymorphism is a risk factor not only for IPF but also other lung 
abnormalities.  
ILD and pulmonary fibrosis more specifically is a common pulmonary 
manifestation of many systemic conditions such as rheumatoid arthritis, systemic 
sclerosis and sarcoidosis [173, 174]. As such, the relationship between rs35705950 and 
increased risk of ILD in these syndromes was investigated. Several studies determined 
that rs35705950 was not associated with the development of interstitial pneumonia or 
pulmonary fibrosis in systemic sclerosis, sarcoidosis, or connective tissue associated 
ILD [48, 51, 83, 168]. However, the variant was associated with a pooled group of ‘other 
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ILDs’ when IPF was removed from the group suggesting that some ILDs may share the 
rs35705950 risk variant[175]. 
ILD is a broad diagnosis. It encompasses a wide variety of diffuse lung 
abnormalities which we divide into subcategories based on HRCT, histology, clinical 
history, and other clinical variables. The clinical prognosis and treatment options are 
also widely varied among ILDs, making it all the more important to differentiate 
between subpopulations. Unfortunately, a definite diagnosis can still be difficult to 
make, particularly early on in disease progression. This difficulty in differentiating 
between diagnoses could be in part responsible for the lack of success in many IPF 
clinical trials as the IPF cohorts may have contained other forms of ILD.   
Although many genetic and environmental risk factors have been identified in 
general as well as within specific ILD subsets, it is still unclear why some individuals 
with a given risk factor develop disease while others do not. Likewise, it remains 
unclear how and why certain risk factors, cigarette smoke for example, can cause 
chronic obstructive pulmonary disease (COPD)—a disease which results in increased 
and less functional airspace within the lung—and IPF—a disease that causes loss of 
airspace. To further complicate our understanding of disease fate, more than one ILD—
such as IPF and COPD—can co-occur in a single individual[129]. 
Understanding the genetic similarities and differences between ILDs could help 
to untangle the link between risk factors and ILDs and aid in differentiating ILDs early 
in disease pathogenesis. It could also help us to better understand the pathogenesis of 
specific ILDs.   I investigated the prevalence of rs35705950 in Caucasian control, IPF, 
hypersensitivity pneumonitis (HP), idiopathic non-specific interstitial pneumonia 
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(iNSIP), chronic obstructive pulmonary disease (COPD) and respiratory bronchiolitis-
associated interstitial lung disease (RB-ILD) cohorts. 
IPF is more aggressive, has poorer survival and has fewer medically relevant 
options than the majority of other ILDs; which necessitates not only differentiation of 
IPF from other ILDs but also earlier diagnosis [129].  Although, lung biopsy is the most 
accurate and sensitive way to diagnose  ILD in most cases, Flaherty et al. determined 
that diagnoses can be variable depending on the biopsy site because of disease 
heterogeneity [176]. Additionally, better understanding of ILD risk factors could lead to 
less invasive diagnostic tools or could be added to current diagnostic measures to more 
accurately diagnose and predict disease risk.  
Idiopathic Pulmonary Fibrosis 
IPF is the most common form of fibrosis ILD [1] with an estimated prevalence of 
100,000 in the United States[12]. IPF is characterized clinically by chronic and 
progressive shortness of breath, non-productive cough, abnormal pulmonary function 
tests, inspiratory crackles and hypoxemia [129]. Fibroblastic foci, honey comb cyst 
formations, and a usual interstitial pneumonia (UIP) pattern are observed with high 
resolution computer tomography (HRCT) and biopsy. Additionally, these features 
typically originate in the distal parts of the lung and progresses more proximally [177]. 
IPF rapidly progresses with an average survival of only 2-5 years [124-128]. High risk 
populations include men[3, 4, 124, 178-180], persons over 60[124, 181-186] and 
smokers[3, 179, 187, 188].  
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 Hypersensitivity Pneumonitis  
HP is typically classified as bronchoalveolar inflammation in response to inhaled 
particulate that leads to granulomas and interstitial inflammation [189]. Clinically, HP is 
characterized by shortness of breath and cough [190]. On HRCT, acute HP can appear 
normal while chronic HP is characterized by ground glass opacities and commonly 
patches of fibrosis [189, 190]. Common irritants associated with HP include birds (bird 
fanciers lung), grain dust (farmer’s lung), and humidifiers (humidifier lung) [189, 190]. 
Although the cause of HP seems obvious in the above examples, bird fanciers lung, for 
example, is not always caused by prolonged exposure to birds but rather can be the 
result of feather pillows or a down jacket. Furthermore, in 25-60% of HP cases no cause 
is ever identified [191]. Additionally, not everyone chronically exposed to inhaled 
particulate develops HP, which suggests an underlying predisposition. The incidence of 
HP ranges from 2-5 per 10,000 individuals [192, 193]. Average survival with HP is 
highly dynamic and depends significantly on whether the trigger is identified. The 
average survival in individuals with HP and a known trigger is 18 years while those 
with unknown triggers have a survival of only 9 years [191]. Morphological 
characterization of chronic HP indicates that it closely resembles IPF in that it can 
contain UIP and fibrotic patches and has a poorer outcome than acute HP [194]. 
Idiopathic Nonspecific Interstitial Pneumonia 
Nonspecific interstitial pneumonia (NSIP) is a common ILD associated with 
connective tissue diseases while idiopathic nonspecific interstitial pneumonia (iNSIP) is 
phenotypically similar to NSIP except for a lack of connective tissue disease. Our study 
population contains only iNSIP patients with no indication of connective tissue or 
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immune disease [195]. Although the clinical features are the same, NSIP is reported to 
have a better prognosis than iNSIP, [196]. The incidence of iNSIP is estimated to be 3 
per million [197]. Clinically, NSIP is characterized by shortness of breath, and cough. On 
HRCT NSIP is characterized by ground glass opacities [195, 198] and other opacities 
similar to IPF, however, unlike IPF, these opacities are homogeneous and evenly 
dispersed throughout the lung[129, 195]. Similarly, honeycombing, which is common in 
IPF is rarely found in NSIP [199]. Additionally, NSIP progression is slow with some 
cases even reporting regression of disease [197, 200]. Lastly, 5 years post diagnosis, 80-
85% survival is reported indicating much better outcomes than IPF [129]. 
Chronic Obstructive Pulmonary Disease  
It is estimated that by 2030 COPD will be the third leading cause of death world-
wide [174, 201]. COPD is characterized by chronic inflammation in the lung, dyspnea, 
emphysema, cough, and airway obstruction and is primarily associated with cigarette 
using [202, 203]. Although COPD is one of the most well studied ILDs, there are no cures 
and response to treatment can be unpredictable [204]. COPD is associated with a minor 
decrease in life expectancy; however, it is also associated with substantially lowered 
quality of life [205]. 
Respiratory Bronchiolitis-associated Interstitial Lung Disease  
RB-ILD is considered a disease of heavy smokers and is unique because of its 
deposition of pigmented particulate and macrophages in the lungs [206-208]. The 
clinical features of RB-ILD include dyspnea, cough, and crackles on inspiration [129]. 
HRCT findings associated with RB-ILD include ground glass opacities [206], reticular 
and nodular opacities [129] , inflammation [209], alveolar septal thickening, and 
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fibrosis with typically normal lung volumes [209]. The prevalence of RB-ILD is higher in 
heavy smokers in their 30’s to 50’s but resolves in many with cessation of smoking 
[210, 211]. RB-ILD is thought to be less common than IPF, however, the prevalence and 
incidence have not been reported due to difficulties in diagnosis[211].  
Methods 
Sample Collection 
Human lung tissues were obtained from the National Heart, Lung, and Blood 
Institute-Lung Tissue Research Consortium (NHLBI-LTRC) and National Jewish Health-
Interstitial Lung Disease Program, including IPF (n=348), HP (n=34), COPD (n=270), 
iNSIP (n=34), RB-ILD (n=15), and non-fibrotic control (n=233) samples. Control tissue 
was obtained from transplant specimens that failed regional lung selection (NJH) or 
biopsies of normal tissue surrounding peripheral lung lesions (NHLBI-LTRC).  The 
diagnoses were determined by a pathology core consisting of 2 pulmonary pathologists, 
a radiology core consisting of 3 pulmonary radiologists, and a clinical core consisting of 
5 pulmonary physicians. All diagnoses were made in accordance with established 
criteria [10, 212]. DNA and RNA were harvested from patient lung and blood using the 
Qiagen DNeasy (Valencia, CA) and Qiagen PAXgene blood kits (Valencia, CA) 
respectively.  
Genotyping and MUC5B Expression 
Whole lung and peripheral blood DNA were used to genotype samples for 
rs35705950 using a pre-validated assay [19]. Total RNA isolated from lung tissue from 
the IPF samples (n=203)  and controls (n=139) was reverse transcribed using the 
SuperScript III reverse transcription kits (Invitrogen, Grand Island, NY) according to the 
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manufacturer’s protocol. MUC5B expression levels were determined using a pre-
validated MUC5B (Hs00861588_m1) Taqman gene expression assay (Applied 
Biosystems, Foster City, CA) and normalized to the pre-validated GAPDH 
(Hs99999905_g1) assay [19]. Relative gene expression data were determined and analyzed using the ∆∆Ct method [213]. 
Statistical Analysis 
To determine genotypic and allelic differences between the control and IPF and 
NSIP populations, we used the Fisher’s exact test with a significance level of p = 0.05. 
Genotype analysis compared the G/G genotype frequency to the combined G/T and T/T 
genotype frequency. Due to the low number of T/T individuals, T/T independent 
analyses were underpowered. The allelic analysis compared the risk allele T to the 
major allele G. To compare MUC5B expression levels for genotype and smoke exposure analysis, we used a standard t test with a significance level of 0.05 comparing ∆CT 
values. Fold changes in MUC5B expression were determined using the previously described ∆∆CT method[213]. CT values below detectable levels were set to a level, representatively zero. For graphical purposes, ∆CT values were inverted (20-∆CT), 
however, all statistical analysis was done on non-inverted values. For smoke exposure 
analysis, individuals were stratified to never or ever (current smokers and those with a 
history of smoking) smoking groups. 
IPF and control data were analyzed using linear regression models analyzing the 
effect of the SNP on MUC5B expression with age, gender, and smoke exposure as 
covariates. Statistical analyses were carried out in GraphPad Prism (GraphPad 
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Software, La Jolla, California USA www.graphpad.com) and R software (Vienna, Austria, 
www.R-project.org).  
Results 
rs35705950 is Associated with IPF and iNSIP 
The IPF (OR = 3.9; 95% CI = 2.7 to 5.7; p > 0.00001) and iNSIP (OR = 2.3; 95% CI 
= 1.1 to 4.8; p = 0.04) populations were more likely to carry at least one copy of the 
MUC5B promoter polymorphism (T) than the controls (Figure 2.1).  In controls the 
allelic frequency of rs35705950 is 11.8%, the majority of individuals were homozygous 
for the major allele (G) (76.4%), and no individuals were homozygous for the variant. 
The majority of the IPF population carried at least one copy of the MUC5B 
polymorphism (54.9%) and 8.3% were homozygous for the variant. Similarly, 41.2% of 
the NSIP population carries at least one copy of the risk variant (Figure 2.1). HP, CODP, 
and RB-ILD did not have significant differences in allelic frequency from controls with 
minor allele frequencies of 14.7%, 8.9%, and 13.3% respectively. 
 
Figure 2.1 Genotypic Frequency of rs35705950 in ILDs 
COPD, RB-ILD, HP, iNSIP and IPF cohorts were genotyped for the common MUC5B promoter 
polymorphism. When compared to the control genotype, IPF and iNSIP showed higher 
frequencies of the GT/TT alleles. *p-value less than 0.05 
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Demographics of MUC5B Expression 
The demographic and clinical characteristics of the subjects are summarized in 
Table 2.1.  There are significant differences between age, gender and smoking status 
between the control and IPF populations, however, linear regression modeling indicate 
that age, gender and smoking status do not significantly contribute to the observed 
difference in MUC5B expression: smoking status (p = 0.4856), gender (p = 0.2406) and 
age (p = 0.0632). Although these variables do not contribute to expression levels, 
history of cigarette use (p = 0.016), increased age (p = 0.0015), and male gender (p = 
9.4x10-6) are all associated with increased risk of IPF.  
MUC5B Expression is Influenced by rs35705950 in Control and IPF Lung Tissue 
Gene expression assays confirm our previous observation that MUC5B 
expression is higher in lung tissue from individuals with IPF compared to controls (11.0 
fold, 95% CI 6.8-17.8, p = 7.1 X 10-20) (Figure 2.2). Similarly, MUC5B expression is 
 
Control COPD RB-ILD HP iNSIP IPF
n=233 n=270 n=15 n=34 n=34 n=348
rs35705950
G/G 76.4% 82.6% 81.3% 73.5% 58.8% 45.1%
G/T 23.6% 17.0% 12.5% 23.5% 41.2% 46.6%
T/T 0.0% 0.4% 6.3% 2.9% 0.0% 8.3%
Cigarette Smoke
Never 63% 94% 73% 53% 44% 62%
Ever 31% 2% 27% 47% 41% 33%
Gender (% male)
45% 55% 27% 29% 47% 65%
Age (mean)
60.1 65.2 49.3 58.4 58.0 63.9
Table 2.1 Clinical Data for ILDs 
 All data represent totals for available data. Smoking status is broken into those who have no history of 
smoking (Never) and either current smokers or those with a history of smoking (Ever). 
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increased in lung tissue from subjects with NSIP when compared to controls (5.0 fold, 
95% CI 1.7-13.8, p = 0.002) (Figure 2.2). Gene expression assays also confirm our 
previous observation that rs35705950 is associated with increased MUC5B expression 
in controls (fold change = 34.1, 95% CI 7.1-162.7, p= 9.8 x 10-6). Additionally, we show 
that rs35705950 is also associated with MUC5B expression in IPF subjects (5.7 fold, 
95% CI 2.3-12.6, p = 6.5 x 10-5) (Figure 2.3). Although the genotype-expression 
correlation had previously been shown in control samples, it had not been observed in 
IPF samples given prior small sample sizes. Similarly, power calculations indicate that 
the iNSIP sample size is too small to analyze the correlation between the MUC5B 
genotype and MUC5B expression.  
Given the interconnected relationship between the genotype at rs35705950 and 
disease, I analyzed populations with and without the SNP independently to determine if 
the SNP status and/or disease status was contributing to MUC5B expression differences 
between the disease populations. In individuals without the SNP, the IPF and NSIP 
groups had higher expression levels of MUC5B than the genotype matched control 
group by 23.4 fold (p < 0.0001) for IPF and 27.3 fold (p = 0.0086) for NSIP. Additionally, 
in individuals with at least one copy of the SNP, MUC5B expression was increased in the 
IPF group compared to controls by 3.7 fold (p = 0.0002); the iNSIP group was 

































Figure 2.2 MUC5B Expression is Upregulated in IPF and iNSIP Lung Tissue 
Inverted delta Ct Values (20- [Ct MUC5B – Ct GAPDH]) are plotted for each control, IPF and iNSIP 
sample.  
* p < 0.05 




Figure 2.3: rs35705950 Contributes to the Expression of MUC5B in the Lung 
Lung MUC5B expression levels are plotted above with each point representing an IPF (red) or a 
control (black) sample. Samples are further separated by genotype at the rs35705950 locus where G 
is the wildtype allele and T is the common variant. Relative expression of MUC5B on the y-axis is 
calculated by subtracting the change in cycle threshold between MUC5B and GAPDH by 20 (the 
highest reading). This process is used to invert the values for graphical purposes.  Statistical analyses 
(two-tailed t-tests) were conducted on non-inverted values.  ** p < 0.0001 
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Cigarette Smoking is Not Associated with MUC5B Expression 
Next, I examined the relationship between MUC5B expression and the MUC5B 
promoter polymorphism while controlling for history of cigarette use. The IPF cohort 
still have higher expression of MUC5B than controls even when stratified by smoke 
exposure (never smokers; 19.4 fold, 95% CI 8.3-45.3, p = 1.9-11: ever smokers; 9.4 fold, 
95% CI 5.0-17.3, p = 2.9-10).  Importantly, no significant differences in the expression of 
MUC5B were observed between never and ever smokers in either the control (p = 0.13) 
or IPF cohorts (p =0.89) (Figure 2.4). 
Linear regression models were used to further explore the impact of smoking, 
rs35705950, age, and gender on the expression of MUC5B. These models indicated that 
MUC5B expression was significantly correlated with having at least one copy of the 
variant (p = 4.8x10-7) and having IPF (p = 1.3x10-8); a history of cigarette smoking, age 
and gender were not significantly associated with MUC5B expression.   
Discussion 
 GWAS and linkage analysis have become common methods for identifying 
genetic risk factors for disease. These genetic risk loci could be used to identify at risk 
populations or differentiate between ILDs early in disease development. Being able to 
predict disease progression from genetic variants relies on the identification of unique 
polymorphisms. On the other hand, shared genetic risk factors suggest shared biological 
processes and could be used to further define the underlying mechanisms of disease. 
The goal of this study was to determine if rs35705950 was a unique risk factor for IPF 





Our findings demonstrate that the minor allele (T) at rs35705950 is associated 
with both IPF and iNSIP. Additionally, MUC5B expression is increased in both IPF and 
iNSIP populations and in association with the variant in IPF and controls. Notably, the 
HP cases likely contained both acute and chronic HP and chronic HP is more 
phenotypically similar to IPF. Further analyses need to be conducted in chronic HP 
independently to determine if rs35705950 is playing a role in this subpopulation of HP. 
These findings suggest that MUC5B may play a role in the etiology and possibly 
pathogenesis of both IPF and NSIP. 
Figure 2.4 History of Cigarette Use Does Not Affect MUC5B Expression 
MUC5B expression is stratified by disease state (Control =Black, IPF= Red) and then by smoking 
history. Smoking history is stratified into never (no smoking history) and ever (current smokers 
and history of smoking) 
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 NSIP is a common histological finding in connective tissue related interstitial 
lung disease, for example scleroderma. However, scleroderma associated interstitial 
lung disease was not previously associated with the promoter polymorphism [48, 214]. 
In addition, there is no association between the MUC5B promoter polymorphism and 
the risk of developing ILD in rheumatoid arthritis[215], or sarcoidosis[48]. In this 
study, all of the NSIP patients were idiopathic (iNSIP) as they did not have serological or 
clinical features which would suggest a yet undefined connective tissue disease. It is 
possible that some of these patients did develop features of a connective tissue disease 
following enrollment into the lung tissue research consortium (LTRC), but longitudinal 
information was not collected.  Regardless of the potential for some iNSIP cases to 
develop connective tissue disease, the observation that iNSIP and IPF share a common 
genetic risk factor reveals a novel relationship between these two entities.  
Recently the MUC5B polymorphism was shown to be associated with increased 
lung abnormalities in a general population suggesting that pulmonary fibrosis 
associated with the polymorphism may be more prevalent than originally thought 
[216]. Additionally, studies in two independent IPF cohorts indicate improved survival 
when the promoter polymorphism is present [217]. In the aforementioned study no 
attempt was made to document the presence of IPF or iNSIP for no lung tissue was 
obtained.  Although these findings suggest an association between disease risk and 
progression, what is potentially more interesting is what these findings could mean for 
fibrotic lung disease in general.  
Although IPF and iNSIP have phenotypic similarities, the affected populations 
vary. The majority of individuals with IPF are male [2], whereas the iNSIP population is 
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predominantly female [218]. IPF has an average age of onset in the early sixties [8], 
whereas onset of iNSIP typically occurs in the early fifties [218]. These differences could 
suggest that IPF and iNSIP are independent conditions or perhaps that they are related 
conditions that are divergent based on environmental or additional genetic risk factors. 
This relatedness is suggested by a small study of 6 individuals, 5 with fibrotic and 1 
with cellular NSIP. All five individuals studied with fibrotic NSIP eventually developed 
UIP, a key indicator of IPF [219]. Additionally, the case of cellular NSIP progressed to 
fibrotic NSIP [219]. Further, the relationship between iNSIP and IPF is strengthened by 
our previous observation that genomic expression profiles of IPF and NSIP are similar 
[46]. Additionally, it has been shown that biopsies taken from different lobes in a single 
individual in 26% of cases are dissimilar representing both IPF and iNSIP. Given that 
iNSIP, not uncommonly, is found in conjunction with IPF, one can postulate that iNSIP 
and IPF are at least related or perhaps even different stages of the same disease.  
Moreover, we have shown, that in familial IIP, families with IPF often also have 
individuals with iNSIP [220]. If IPF and iNSIP represent diseases with a common 
pathway and divergent phenotypes we may be able to enhance our understanding of 
both diseases through understanding of either. Additionally, as we continue to develop 
treatment options for IPF, they may also prove effective for iNSIP. The MUC5B promoter 
polymorphism is a common risk factor for IPF and iNSIP and the most substantial 
genetic factor for the development of both IPF and iNSIP. However, other factors such 




These data establish the MUC5B promoter polymorphism rs35705950 as a novel 
genetic risk factor for iNSIP and suggest a genetic relationship between IPF and iNSIP. 
This genetic link adds to the growing body of evidence which suggests shared biological 
mechanisms underlying IPF and iNSIP.  
Cigarette smoke exposure (CSE) is the most highly associated environmental 
risk factor for IPF [3, 181, 187]. Although CSE is highly correlated with IPF, the 
mechanism of this association is unclear but may be related to epigenetic gene 
regulation within the lung [214].  We sought to determine if CSE was regulating MUC5B 
expression in the lung. Although CSE has previously been shown to correlate with 
MUC5AC expression in vivo and in vitro, CSE does not alter MUC5B expression in our 
lung tissue cohort in either our control or IPF populations. Although previous work has 
shown a correlation between mucin expression and cigarette smoke exposure in lung 
tissue, the primary mucin affected is MUC5AC [221-223], not MUC5B. Decidedly, our 
cohort is limited in finding association between MUC5B expression and cigarette smoke 
exposure. Firstly, the tissue samples contained a mixture of cells and different ratios of 
cells in each of the samples may alter the observed MUC5B expression. Secondly, 
cigarette smoke exposure was self-reported and therefore potentially biased. 
Mucins are dysregulated in a number of pulmonary diseases and play unique 
roles in healthy and diseased lungs. I show here that MUC5B upregulation is associated 
with both IPF and iNSIP and may suggest common biological processes. Additionally, 
cigarette smoke, although it is the strongest environmental risk factor for IPF, does not 
appear to regulate MUC5B expression in the lung suggesting either that cigarette smoke 
and mucin overproduction indicate two independent pathways in IPF development or 
32 
 
conversely that cigarette smoke works in tandem with over production of MUC5B to 





DNA METHYLATION OF THE MUC5B PROMOTER IN IPF 
Introduction 
  Epigenetic alterations are associated with a wide variety of diseases including 
cancers (reviewed in [224]), imprinting disorders [225], and more recently lung 
diseases [226, 227]. IPF is associated with genome-wide changes in chromatin structure 
[228-230] and DNA methylation [231-235]. Although many changes in the epigenome 
have unknown function, we are beginning to elucidate those associated with IPF. A 
recent study by Yang et al. identified over 2,000 differentially methylated regions 
(DMRs) of which almost half were associated with changes in gene expression [113]. 
We also know that many risk factors for IPF are also known to change DNA methylation 
patterns, such as, cigarette smoke exposure[187, 236], aging [34, 236, 237], asbestos 
exposure [236, 238, 239], male gender [237, 240], relatedness[237, 241] and 
ethnicity[242, 243]. 
In the human genome, DNA methylation most commonly occurs at the 5’ carbon 
of cytosine residues within CpG (5’-cytosine-phosphate-guanine-3’) dinucleotides. 
These dinucleotides are uncommon throughout the genome due to high rates of 
mutagenesis of the methylated cytosine residues to thymine through deamination[244]. 
However, dense clusters of CpGs, referred to as CpG islands, are found in more than 
50% of all genes [105] and as early as the 1970’s it was predicated that DNA 
methylation was associated with gene expression [244, 245].  
The association between DNA methylation and transcriptional regulation is 
complex; at some loci DNA methylation regulates transcription [121] while other loci 
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transcription leads to demethylation[246]. Additionally, the original concept that DNA 
methylation acts strictly as an inhibitor of transcription appears to be overly simplified. 
Although the canonical inverse relationship between DNA methylation and 
transcription appears to be more common at CpG islands near transcriptional start sites 
(TSSs), methylation of CpG islands within gene bodies show higher rates of positive 
correlation[247].  
Although methylation patterns can be inherited and genetically determined 
[241], environmental factors also play a substantial role in modifying the methylome. 
The environmental contribution to DNA methylation patterns has been studied in many 
ways including in vitro exposures, animal models, exposure questionnaires in humans, 
and twin studies. Using cell lines and primary cell cultures, it has been shown that both 
gene specific and genome wide changes occur in response to a variety of exposures 
including cigarette smoke, automobile exhaust, and dietary folate [248, 249]. Animal 
exposures capture the environmental effects on methylation not only at an organismal 
level but also on a tissue specific context. Although in vitro and animal models do not 
necessarily recapitulate the human body and questionnaires are inherently flawed due 
to inaccurate reporting, twin studies provide profound evidence for the effect of the 
environment on the methylome over time. In multiple studies, it has been shown that 
although identical twins have nearly identical methylation patterns at birth, their 
methylomes diverge over time [250, 251].  
 DNA methylation patterns are associated with a number of phenotypes but for 
many diseases, it is difficult to determine if the observed methylation changes are the 
cause or result of disease. This is particularly difficult for diseases such as IPF where the 
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disease is often diagnosed late in disease progression. This is further complicated by 
environmental risk factors for IPF which are known to cause changes in DNA 
methylation. Being able to tease out the DNA methylation changes that are associated 
with disease from those associated with a share environmental exposure is difficult 
with self-reporting.  
Background  
Given what we know about IPF and epigenetic marks, several lines of evidence 
support a critical role for control of gene expression in IPF lung by DNA methylation 
and histone modifications. Firstly, IPF is a disease of the elderly and changes in DNA 
methylation, histone modifications, and gene expression occur as we age [252-254].  
Genome-wide studies in aging cells and tissues have revealed the occurrence of 
stochastic changes in DNA methylation, also referred to as drift [255]. This drift leads to 
isolated regions of hyper and hypomethylation as well as increased variability in 
methylation across the genome [253].  Stochastic profibrotic DNA methylation drift 
could predispose to the development of the disease in susceptible individuals [256].  
Secondly, IPF is an environmental lung disease [257, 258]. It is well established 
that environmental exposures also strongly influence epigenetic marks [259]. Cigarette 
smoke, the main environmental risk factor for IPF, has an influence on the methylome 
[260-262] and on methylation of specific promoters in genes involved in pathogenesis 
of IPF such as WNT7A [263]. Recent work identified extensive genomic changes in DNA 
methylation in small airway epithelium (SAE) of smokers compared to smokers with 
corresponding modulation of gene expression [264]. Other recent studies have shown 
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how cigarette smoke influences histone modifications and chromatin accessibility [265-
267].  
Thirdly, IPF is also a genetic disease [49, 50, 268], and specific genetic factors 
have also been shown to influence epigenetic marks. An individual’s genetic 
background influences epigenetic marks in two ways; by direct inheritance (imprinted 
loci) [269] and by genetic variants that segregate with disease exerting their effects 
through epigenetic modifications, such as the case of haplotype-specific methylation. In 
addition to investigation at specific loci, genome-wide studies demonstrate a strong 
genetic component to inter-individual variation in methylation [270-272] and histone 
modification profiles [273-275]. Similarly, gender is known to play a role in tissue 
specific DNA methylation patterns [237, 276-279] and being of male gender is a risk 
factor for development of IPF [12]. 
Finally, epigenetic marks are crucial in lung development and aberrant 
recapitulation of the developmental program following injury is a hallmark feature of 
IPF [38]. DNA methylation and histone modifications determine cell fate during organ 
development by controlling tissue-specific expression [280]. Epigenetic control of gene 
expression is also involved in lung epithelial cell differentiation [281] and 
developmental pathway signaling [282, 283].  
Several targeted studies have shown that epigenetic modulation (both DNA 
methylation and histone marks) regulates expression of genes and miRNAs involved in 
pathogenesis of IPF (Table 3.1), namely, cyclooxygenase-2 (COX2) [228, 284, 285], 
chemokine IP-10 [286], Thy-1 (CD90) [232, 287],  p14(ARF) [288], α-smooth muscle 




Genes/Genomic Loci  Epigenetic 
Mechanism 
Tissue or Cell Phenotypes and 
Outcomes 
cyclooxygenase-2 
(COX2) [228, 284] 
DNA methylation; 










   
Thy-1 (CD90) [232, 
287] 
DNA methylation; 
H3K4me3 and H4 
acetylation 




p14(ARF) [288] DNA methylation Human lung 
fibroblasts 
IPF; apopotosis 
α-smooth muscle actin 
(α-SMA) [234, 235] 
DNA methylation; 
methyl CpG binding 








Human lung tissue 
and human lung 
fibroblasts 
IPF; collagen deposition 
BAK, BCL-XL, FAS 
[149, 229] 




Human and mouse 
lung fibroblasts 
Fibroblast apoptosis 
NOX4 (103) H4K16Ac and 
H4K20Me3; 
IMR-90 human fetal 
lung fibroblast cell 
line 
Cell senescence 




lung tissue, and A549 
lung epithelial cell 
line 
Innate immunity; EMT 
Mmp9 [291] histone acetylation; 
SIRT1 
Mouse lung tissue TGF-β1 signaling and lung 
development 
CpG islands [233, 292] DNA methylation Human lung tissue IPF  
CpG islands [293] DNA methylation Human lung 
fibroblasts 
IPF 
2.1M CpG motifs in the 
genome [113] 
DNA methylation Human lung tissue IPF 
of high relevance to pulmonary fibrosis are also epigenetically regulated; this has been 
demonstrated specifically for fibroblast apoptosis [149, 229], cell senescence [294], cell 
migration[295], and innate immunity [290] in IPF. These studies of DNA methylation 
and histone modifications in specific genes, miRNAs, and molecular processes have also 
Table 3.1 Summary of Studies of DNA Methylation and Histone Modifications Performed to 




shown a direct link to fibroproliferative phenotypes. For example, Dakhlallah et al. 
identified a DNMT1-controlled feedback loop that contributes to the IPF fibroblast 
phenotype and ECM deposition [289]. Another study has linked TGF-β1 signaling, lung 
development and histone modifications [291]. Lastly, a study by Korfei et al 
demonstrated that the family of histone deacetylation proteins are all up-regulated in 
IPF lung and associated with increased cell proliferation and survival[296]. Taken 
together, these targeted studies have provided crucial information on the role of DNA 
methylation and histone modifications in regulation of gene expression in some of the 
key genes, miRNAs, pathways, and molecular processes that are hallmarks of IPF. 
Genome wide assessments of epigenetic marks in IPF are currently limited to 
DNA methylation profiles. The first two studies of genomic methylation profiles of IPF 
lung tissue used arrays with probes covering CpG islands and promoters. Despite the 
limited coverage of early array platforms the first two studies of genomic methylation 
profiles identified extensive DNA methylation changes in IPF lung tissue  
[233, 292]. A more recent study used the same platform as in Sanders et al. [233] to also 
show substantial changes in DNA methylation in fibroblasts, the key effector cell in 
fibrosis, of patients with IPF compared to controls [293]. 
The most comprehensive study of IPF lung tissue to date, led by our group,  
interrogated 4.6 million CpG sites distributed across the human genome in lung tissue 
of 94 subjects with IPF and 67 controls [113]. This analysis identified 2,130 significant 
differentially methylated regions (DMRs), of which 60% are in CpG island shores, 
similar to published findings in cancer [297]. 738 DMRs are associated with significant 
changes in gene expression and enriched for canonical inverse relationship between 
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methylation and expression. An additional analysis of the relationship of methylation 
marks to expression changes identified methylation marks that control both cis and 
trans regulation of gene expression, with an enrichment for cis relationships. This 
analysis also identified five trans relationships where a methylation change at a single 
DMR is associated with transcriptional changes in a substantial number of genes; four 
of these DMRs are near transcription factors. Taken together, these findings suggest not 
only widespread DNA methylation changes in IPF lung tissue but also a substantial 
effect of these methylation changes on gene expression. While it is unknown whether 
the methylation changes we have identified are the result of the disease or are 
causative, given that several risk factors for IPF are independently associated with 
changes in DNA methylation, it is likely that the latter at least contributes to the 
methylation pattern. 
In addition to replication of the published findings, one of the most important 
directions for the field of IPF epigenomics is to begin to understand cell specific 
patterns of DNA methylation and gene expression in the lung. For example, our study 
showed hypermethylation and reduced expression of the CASZ1 transcription factor in 
whole lung tissue but the same DMRs were hypomethylated in alveolar type II cells 
isolated from IPF lungs [113]. In accordance with these findings, immunohistochemical 
staining showed loss of expression in airway epithelium and concomitant increase in 
expression of CASZ1 in the alveolar epithelium in IPF lung tissue sections compared to 
histologically normal lung [113]. Isolation of specific cell types would also allow for 
profiling of histone modifications to paint a more complete picture of the role of 
epigenetic regulation of gene expression in IPF lung.  
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Although cell type specific methylation patterns in lung tissue are the most 
relevant to understanding the underlying biology of IPF, on a clinical level, the benefit of 
mapping disease progression over time with repeat biopsies or determining early 
disease risk by lung biopsy does not outweigh the risks of lung biopsy. Surrogate 
tissues, mainly peripheral blood, may be suitable to develop epigenetic mark-based 
biomarkers of disease and potentially response to therapy. At this time, studies 
comparing the changes in methylation pattern associated with IPF in the lung to those 
in the blood have not been performed; it has, however, been shown that there are IPF 
specific methylation changes in cell free blood DNA[298]. This suggests a possible 
method by which epigenetic marks could be used to further diagnose and classify IPF 
using a minimally invasive sampling technique.   
Recent work in the field of genetics of IPF has made it clear that there is a strong 
genetic component to this disease. Common genetic variants in the 10 loci identified by 
Fingerlin et al. using a GWAS explain ~30% of the disease risk [49]. We intersected the 
2,130 IPF-associated DMRs with recently identified loci by the two published GWAS in 
IPF [49, 50] and identified methylation changes in genes within 5 of these loci [113].  Of 
special interest are genes that are differentially expressed in IPF lung and whose 
expression may be regulated by both genetic variants and DNA methylation. As more 
genetic discoveries are made and the loci that have already been associated with fine 
mapped, it is highly likely that additional candidate genes will emerge.  
 Of specific interest is the common MUC5B promoter polymorphism rs35705950. 
This variant is upstream of MUC5B and is associated with MUC5B expression suggesting 
that it affects a regulatory domain. Although rs35705950 correlates with MUC5B 
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expression, it does not explain all of the disease associated increase in MUC5B nor does 
it explain the wide range of MUC5B expression. Interestingly, the variant is a guanine 
(G) to thymine (T) transversion at a CpG dinucleotide within a CpG island. The 
polymorphism affects the capacity of that dinucleotide to become methylated and may 
also affect regional methylation and/or may work in tandem with changes in the DNA 
methylation to regulate MUC5B expression. I hypothesized that methylation within the 
MUC5B promoter/enhancer is association with the variant, contributes to MUC5B 
expression, and is a risk factor for the development of IPF. 
Methods 
Samples  
Human lung tissue derived RNA and DNA were obtained from the National Heart 
Lung and Blood Institute-Lung Tissue Research Consortium (NHLBI-LTRC) and 
National Jewish Health-Interstitial Lung Disease Program, including IPF (N=247) and 
non-fibrotic control (N=131) samples (Table3.2). Control tissue was obtained from 
transplant specimens that failed regional lung selection (NJH) or biopsies of normal 
tissue surrounding peripheral lung lesions (LTRC).  The diagnosis of IPF was 
determined by a pathology core consisting of 2 pulmonary pathologists, a radiology 
core consisting of 3 pulmonary radiologists, and a clinical core consisting of 5 







Genotyping and Expression 
Whole lung (Qiagen DNeasy, Valencia, CA) and peripheral blood DNA (Qiagen 
PAXgene blood kits, Valencia, CA) were used to genotype each individual for 
rs35705950 using a pre-validated assay [19]. Total RNA was isolated from lung tissue 
of cases and controls and reverse transcribed using SuperScript III reverse 
transcription kits (Invitrogen, Grand Island, NY) according to the manufacturer’s 
protocol. MUC5B expression levels were determined using a pre-validated MUC5B 
(Hs00861588_m1) Taqman gene expression assay (Applied Biosystems, Foster City, 
CA) and normalized to the pre-validated GAPDH (Hs99999905_g1) assay [19]. Relative gene expression data were determined and analyzed using the ∆∆Ct method [213]. 
DNA Methylation 
DNA methylation was determined using a custom EpiTyper panel by Sequenom 
(San Diego, California). Of the 147 tested CpG motifs, 24 CpG motifs did not pass quality 
control and 18 CpG motifs combined with adjacent motifs into a single signal due to 
G/G G/T T/T G/G G/T T/T
 n (%) 103 (79%) 28 (21%) -- 120 (49%) 104 (42%) 23 (9%)
Gender (%Male) 50% 46% -- 64% 70% 48%
Average Age (Std) 58 (14.6) 57 (14.2) -- 63 (8.8) 65 (8.0) 64 (8.2)
Smoking (n)
Ever 59 15 -- 74 70 11
Never 37 11 -- 40 28 10
IPFControls
Table 3.2: Sample Population for Methylation Analysis 
DNA methylation patterns were analyzed in lung tissue for the below populations (which vary slightly 
from the expression and genotyping population based on tissue availability). Smoking data is 
represented as Ever (those who no longer smoke but have a history of smoking and current smokers) 
and Never (those who report no history of smoking). Not all samples had available smoking data. 
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proximity of CpG motifs, leaving a total of 109 signals. Additionally, 2 IPF and 6 control 
samples failed quality control and were removed from further analysis.  
Statistical Methods 
Methylation data were analyzed using the R statistical software (Vienna, 
Austria). Logistic regression modeling and generalized linear regression model were 
used, where appropriate, to determine association of CpG methylation to each variable; 
disease state, rs35705950 genotype, and MUC5B expression. Next, p values were 
modeled using the comb-p method for DMR detection [299].  
For the proportion effects analysis, logistic regression modeling was completed 
in the R statistical software (Vienna, Austria). The dependent variable was disease state 
(IPF or control) and the independent variables (rs35705950, DNA methylation and 
MUC5B expression) were each tested first in single variable models, then in two 
variable models and lastly together as a complete model. 
Results 
 DNA methylation of 109 CpG motifs across the 4KB region upstream of MUC5B 
was assayed in lung tissue of non-fibrotic controls and IPF. Methylation of this region 
was dynamic with mean methylation of a single CpG ranging from 15% to 98% and 
range of methylation at a single CpG varying as little as 8% and as much as 100%. 
Additionally, specific CpG motifs showed bi- and tri modal distributions that were 
concordant or discordant between cases and controls. Histograms depicting 
distribution of DNA methylation in cases and controls are in Appendix A.  
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MUC5B Expression, IPF and rs35705950 Associated DMRs 
IPF was found to be associated with 2 differentially methylated regions (DMRs) 
in the region 4kb upstream of the MUC5B TSS (Figure 3.1). The 5’ most disease-
associated DMR consists of 25 CpG motifs that are hypermethylated in IPF lung, and 
includes the MUC5B promoter variant rs35705950 (Chr11: 1241086-1241658, p = 8.8 x 
10-59). The smaller disease-associated DMR consists of 4 CpG motifs that are 
hypomethylated in IPF compared to controls (Chr11:1244003-1244077, p = 2.5 x 10-7) 
and is immediately upstream to the transcription start site (Figure 3.1.A). Both disease-
associated DMRs are within areas of open chromatin, and have P300 and 
H3K27acetylation ChIP-seq marks (Figure 3.2), which suggests potential promoter or 
enhancer activity. 
Irrespective of disease state, MUC5B expression was found to be associated with 
a DMR that includes 11 CpG motifs that are hypermethylated in association with 
increased expression of MUC5B and contains the MUC5B promoter variant rs35705950 
(Chr11: 1241139-1241412, p = 4.19 x 10-6)(Figure 3.1.B). This non-canonical positive 
correlation between expression and methylation is likely explained either by inhibiting 
binding of a repressive element or binding of a transcription factor that binds with 
higher affinity to methylated DNA [300, 301].  
Univariate analysis of the MUC5B promoter variant rs35750590 and methylation 
established an association between the promoter variant and a single DMR containing 
34 CpG motifs and including the promoter variant (Chr11: 1240989-1241950, p = 
1.08x10-39)(Figure3.1.C). The MUC5B variant is primarily associated with 
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Figure 3.1 Methylation Analysis of the MUC5B Promoter 
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Figure 3.1 Methylation Analysis of the MUC5B Promoter  
Linear and logistic regression modeling were performed to determine the association between 
DNA methylation in the 4KB region directly upstream of the MUC5B TSS and IPF, MUC5B 
expression and the MUC5B promoter variant. The linear and logistic regression models were 
further analyzed by comb-p, a statistical package which identifies statistically similar regions to 
identify DMRs. The significance threshold indicated by the horizontal line on each graph indicates 
a stringent line for multiple testing correction. The vertical purple line indicates the location of the 
MUC5B variant. A. Disease Associated DMR: Logistic regression modeling of IPF and DNA 
methylation with covariates (age, gender, smoking status and genotype at rs35705950). B. 
MUC5B Expression Associated DMR: Linear regression modeling of MUC5B expression and DNA 
Methylation. C. rs35705950 Associated DMR: Logistic regression modeling of the common 




hypermethylation of the DMR; however, the 3’ most region contains CpG motifs which 
are hypomethylated in association with the risk variant.  
Given the strong association between IPF and DNA methylation and the high 
correlation between rs35705950 and IPF additional analyses were performed to 
disentangle the relationship between DNA methylation and the variant in cases and 
controls separately. When the samples were divided into cases and controls and then 
the association between DNA methylation and rs35705950 was re-analyzed in each 
group the results vary slightly from the pooled analysis. In non-fibrotic controls, 4 
DMRs are associated with the polymorphism (Chr11:1240712-1241950 p = 2.13 x 10-
213, Chr11:1242061-1242473 p = 2.69 x 10-14, Chr11:1242702-1243421 p = 3.67 x 10-77, 
Chr11:1243606-1243691 p = 6.14 x 10-4). In subjects with IPF, the association identifies 
a single DMR which lies within one of non-fibrotic DMRs (Chr11:1241559-1241849 p = 
2.82 x 10-14) (Figure 3.3).  This finding suggests that the MUC5B promoter variant itself 
may differentially affect methylation patterns in the MUC5B promoter in subjects with 
IPF. 
When the DMRs from each of the univariate analyses are aligned, an overlapping 
DMR is evident that includes 11 CpG motifs that are associated with IPF, MUC5B 
expression, and the MUC5B promoter variant. This region is hyper-methylated in 
association with IPF, increased expression of MUC5B in lung tissue, and the 
rs35705950 risk allele (T). These methylation data helps to define a regulatory region 
and suggest a role for DNA hypermethylation in the regulation of MUC5B and as a risk 





Figure 3.2 Transcription Factor Binding at rs35705950  
 The ENCODE project ChIP-Seq data set indicates binding of 19 transcription factors in regions overlapping the MUC5B variant. Darker bands 
indicate higher occupancy of the tested transcription factor and the green areas indicate conserved binding motif positions.   
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Figure 3.3 SNP DMR in IPF and Control Lung  
When the SNP associated DMR is analyzed in control (A) and IPF (B) lung tissue separately, it becomes 
evident that the effects of the polymorphism on regional methylation become less wide spread in IPFs. 
There are 4 DMRs associated with rs35705950 in the control populations (Chr11:1240712-1241950 
p=2.13 x 10-213, Chr11:1242061-1242473 p=2.69 x 10-14, Chr11:1242702-1243421 p=3.67 x 10-77, 
Chr11:1243606-1243691 p=6.14 x 10-4) while there is only 1 DMR in the IPF population 
(Chr11:1241559-1241849 p = 2.82 x 10-14). The CpG motifs within the IPF DMR are also differentially 
methylated in the control analysis. This result is not surprising given that we also see a larger and more 






Table 3.3 Logistic Regression Modeling of IPF Risk Factors 
 IPF is independently associated with rs35705950, MUC5B expression and DNA methylation of the 
overlapping DMR. When the association between IPF and rs35705950 is corrected for by either 
MUC5B expression or DNA methylation, rs35705950 loses significance while MUC5B expression and 
DNA methylation remain highly significant. When rs35705950, MUC5B expression, and DNA 
methylation are in a single model, we see that DNA methylation and MUC5B expression are 
independent variables while rs35705950 is dependent. It is also important to note that although 
MUC5B expression appears protective, this is the result of higher ∆CTs reflecting lower expression; 




Logistic Regression Modeling of IPF Risk Factors 
Logistic regression modeling was used to determine which factors in the DMR 
analyses are independent risk factors for IPF (Table 3.3). Univariate analyses 
demonstrate that IPF is independently associated with the overlapping DMR (p = 2.0 x 
10-16), the promoter variant (p = 1.0 x 10-7) and MUC5B expression (p = 2.7 x 10-13). 
When we include all of the factors into a single analysis the overlapping DMR (p = 1.7 x 
10-14) and MUC5B expression (p = 3.1 x 10-8) remain significant, however, the variant 
becomes less strongly associated with disease (p = 0.03). This suggests that the effect of 
the variant on disease risk is modulated primarily through its effect on methylation and 
gene expression. It is also curious that the effect of methylation on disease risk does not 
appear to be primarily modulated through gene expression. 
Discussion 
The common MUC5B promoter variant affects expression of MUC5B in both 
control and IPF lung; however, the mechanisms underlying this association have yet to 
be investigated. Several lines of evidence suggested a role for epigenetic changes in IPF 
including whole genome DNA methylation analysis [21].  Additionally, although the 
polymorphism plays a role in regulation, the variability of expression suggests that 
additional factors regulate MUC5B expression. DNA methylation was investigated as a 
potential downstream effect of rs35705950 as well as an independent regulator of 
MUC5B expression.  
MUC5B promoter methylation was investigated using a mass spectrometry 
based methylation method. With this detailed methyl-map we were able to define a 
region of the MUC5B promoter that is differentially methylated in association with IPF, 
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rs35705950 and MUC5B expression. This region, which we refer to as the overlapping 
DMR, is particularly interesting given that it also contains the common MUC5B 
promoter polymorphism and a CpG island. Additionally, the overlapping DMR contains 
a region that has been identified by the ENCODE project as an area of open chromatin 
with ChIP-seq identified binding of several transcription factors, and other chromatin 
features consistent with regulatory regions further suggesting the importance of this 
region.  
There are several factors which are significant modifiers of IPF risk, many of 
which are also independently associated with global changes in DNA methylation and 
could therefore play a role in MUC5B regulation. Cigarette smoke exposure, the leading 
environmental risk factor for IPF [187], is associated with significant changes in DNA 
methylation [22]. Another major risk factor for IPF is increased age, with a mean age of 
onset of 55[302]. As individuals age, certain regions of the genome become either more 
or less methylated. Methylation also becomes more divergent in aged populations. In 
other words, as individuals age, for example identical twins, which have very similar if 
not identical methylation patterns at birth have continuously diverging methylation 
patterns as they age. This has been noted in support of the hypothesis that the 
environment causes changes in the methylome. In IPF, a disease with known genetic 
risk factors but a late age of onset, we predict that a combination of age related and 
exposure related changes in DNA methylation contribute to the onset or pathogenesis 
of IPF.  
 Given the complexity of IPF, it is likely that both gene-gene and gene-
environment interactions contribute to the onset and progression of IPF. Here we show 
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a complex interplay of genetic and epigenetic modifications in both non-fibrotic control 
and IPF samples. Combining our knowledge of genetic and epigenetic aberrations 
associated with IPF may help explain the lack of penetrance of the MUC5B promoter 
polymorphism or a portion of the missing heritability in familial IPF.  Although the 
variant is associated with increased risk of IPF, development of IPF likely requires 
multiple hits. The polymorphism increases MUC5B expression and creates an 
environment in the lungs where repair and immune functions are modified.  However, 
unless the lungs are further challenged, these modified conditions may still allow for 
adequate lung homeostasis. As a person ages and is exposed to inhaled particulate 
matter and viral insults, the lungs sustain damage. In a person with increased MUC5B 
expression, the response to this insult may be increased damage or fibrosis. Even 
exposures that do not cause direct damage could leave a fingerprint in the form of DNA 
methylation modification. We are aware that many exposures including cigarette smoke 
lead to global changes in the methylation pattern of lung DNA even when genetic 
modifications are not observed. Given our findings in this study we hypothesize a model 
in which the MUC5B promoter variant contributes to IPF disease risk directly through 
modification of MUC5B expression and indirectly through modification of the local 
methylome. Additional modifiers of methylation, such as aging, either contribute to or 
counteract the deleterious methylation marks in the MUC5B promoter. In this model, 
methylation changes could be considered the second hit. In this way, the variant and 
DNA methylation contribute to increased risk of IPF as a single signal as well as DNA 
methylation contributing as an additional independent signal.  
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Although the canonical perspective is that gene expression and methylation have 
an inverse relationship, methylation of the MUC5B expression-associated DMR is 
positively correlated with MUC5B expression. One possibility is that the nuclear protein 
that binds this region is a transcriptional repressor. As such, inhibition of repressor 
binding can lead to increased transcription. Likewise, some transcriptional inducers 
bind more favorably to methylated DNA or require methylation marks for adequate 
binding. Which factors bind to this region and, perhaps more importantly, which bind 
differentially based on the genotype at rs35705950 and DNA methylation remains 
unknown.  
IPF is an elusive disease, difficult to understand in every aspect; cause, 
pathogenesis, progression, and treatment options. GWAS and linkage analysis studies 
were the first step in teasing apart the biology of IPF. In depth annotation of the genetic 
loci through epigenetic mapping, structural studies and mechanistic analysis is 
necessary to fully understand not only how these loci lead to disease but also how we 
can intervene. The DMRs that I identified in this study indicate that hypermethylation of 
this region may lead to dysregulation of MUC5B expression and may be an additional 
risk factor for IPF. Although we are not yet able to induce targeted changes to the 
methylome new CRISPR based technologies are being tested for this purpose and it is 




VALIDATION OF RS35705950 AS A REGULATOR OF MUC5B ENHANCER ACTIVITY 
*Portions of this Chapter adapted from [285] 
Introduction 
 The importance of the MUC5B variant rs35705950 as a predictor of IPF risk has 
been well established. Additionally, we are now aware that this variant is associated 
with regulation of MUC5B expression in both control [19] and IPF lung. Although these 
associations are clear, it remained unknown whether rs35705950 was directly affecting 
enhancer activity or if it was indirectly associated with regulation. Specifically, given 
the strong correlation between rs35705950 and DNA methylation patterns in the 
promoter, it is possible that the effect of the variant on regulation of MUC5B expression 
could be modulated through epigenetic changes. Understanding the link between 
rs35705950 and MUC5B regulation could help us to confirm a causal role for the variant 
in MUC5B dysregulation and may lead to the identification of novel genetic variation 
associated with regulation and IPF risk that may have been missed do to rarity or small 
effect size.  
Background 
 GWAS and linkage analysis have been used to identify over 1,000 loci associated 
with a variety of phenotypes [303]. Of these loci, nearly 90% are found in non-coding 
regions of the genome [303] and as such it is likely that gene regulation plays a 
substantial role in disease as well as normal variation. Although the coding and non-
coding variants are predicted to have a variety of functions, few have been validated 
functionally [303].  
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Similar to other studies, the common the MUC5B promoter variant was identified 
in a linkage analysis and has been associated with a biological change but the 
mechanisms underlying these associations in unknown. Additionally although the 
variant in associated with increased expression of MUC5B, there is no evidence to 
indicate that this relationship is causal. Furthermore, there is variability in MUC5B 
expression which is not related to the variant, indicating that there are other factors 
which contribute to regulation of MUC5B. To further investigate this association and 
determine if rs35705950 was sufficient to alter MUC5B expression, we created a 
promoter reporter and used site directed mutagenesis to observe the effects of the 
variant.   
Methods 
Study Population, Lung Tissue, and Isolation of DNA 
DNA was obtained from 12 consented non-Hispanic white patients with IPF from 
the Lung Tissue Research Consortium (LTRC). Of the 12 samples, 6 were homozygous 
for the wildtype allele at rs35705950 and 6 were homozygous for the variant. One allele 
from each patient was used for plasmid construction.  
Cell Lines 
A549 cells were cultured in Ham’s F-12 medium (Lonza, Basel, Switzerland) and 
LC2-ad cells were grown in RPMI medium both with 10% fetal bovine serum, penicillin 
(100 IU/ml) and streptomycin (100ug/ml) at 37°C in a water-jacketed incubator with 
5% CO2.  
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Cloning and Transfection 
A 4.2 kb region (GRCh37/hg19 Chr11:1240119-1244353) 5’ to the transcription 
start site of the MUC5B gene that includes the rs35705950 (Chr11:1241221) variant 
was amplified using the Phusion High-Fidelity DNA polymerase (New England Biolabs, 
Ipswich, MA). The PCR amplicons were cloned into pCR2.1-TOPO vector (Life 
Technologies, Carlsbad, CA) and site-directed mutagenesis was performed to introduce 
an Nhe-I restriction site at the ATG site for subcloning. Cloned sequences were 
confirmed by Sanger sequencing, and subcloned into the pGL4.10 vector (Promega, 
Fitchburg, WI). Site-directed mutagenesis was performed to convert the rs35705950 
variant (G to mutated-T and T to mutated-G). All plasmids used for transfection 
experiments were prepared using an endofree plasmid maxi kit (Qiagen).  Each plasmid 
was assayed six times in three separate experiments using Standard transfection 
techniques and reagents in A549 cells.  
For the replication cohort, LC-2/ad cells were transfected with the reporter 
plasmid, SV40-renilla and mCherry at a ratio of 10:1:1 using Lipofectamine 2000 
(Thermo Fisher Scientific). The replication was conducted on 3 of the original 
constructs with their paired mutants. The empty vector was pGL4.10 without the insert. 
Twenty-four hours after transfection, luciferase activity was assayed using the Promega 
Dual Luciferase Reporter assay and luciferin levels were normalized to renilla levels. 
The addition of mCherry was to validate transfection efficiency.  
Statistics 
Student t-test and Chi square test were used for clinical background data 
analysis. Student t-test and paired t-test were used for promoter activity analysis. Since 
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our hypothesis was that the T genotype would lead to increased promoter activity, a 
one-tailed statistical test was applied to all comparisons.  
Results 
# Indicates figures and work of Yasushi Nakano 
MUC5B Promoter Construct and Mutagenesis 
In the 12 DNA samples, there were 16 SNPs (1 novel) within the 4.2 kb 5’ 
promoter region. None of these variants resided in the previously identified 
overlapping DMR. Each subject had a unique haplotype for the putative MUC5B 
promoter region in the assayed allele (Figure 4.1.A and 4.1.B).  
To determine whether the MUC5B promoter variant modulates MUC5B promoter 
activity, a standard luciferase assay was performed with the plasmids from 12 subjects 
(G [N=6] and T [N=6]) with IPF. We excluded one sample as an outlier because the 
sample repeatedly showed much higher luciferase activity than all other samples. 
Results from the luciferase assay for the remaining 11 samples demonstrated that the 
MUC5B promoter activity of the T group was significantly higher than that of the G 
group (p < 0.05, Figure 4.1.C). This validated the previous association between the T 
allele and MUC5B expression in this synthetic model.  
To account for the potential impact of these other promoter variants and to 
examine the sole effect of rs35705950, we performed site-directed mutagenesis and 
created plasmids which had the opposite genotype for rs35705950. We then compared 
the MUC5B promoter activity between the original samples and samples that we had 
converted at rs35705950 using site-directed mutagenesis. When the wild type was 






Figure 4.1 MUC5B Promoter Clones, Haplotypes and Promoter Activity# 
A/B. Schematic representation of the MUC5B 5’ promoter region for the 12 IPF patients with either 
G or T genotypes: There were 16 variants in the 4.2kb region immediately 5’ to the MUC5B 
translational starting site (ATG). Each patient had a different combination of variants. ● indicates 
the presence of the minor allele at each site. C. MUC5B promoter activity of the variant (T) group 
was significantly higher than that of the wild type (G) group. The A549 cell line was used for the 
promoter assay. Data are representative of mean ± SEM (n=5, 6). An unpaired t-test (one tailed) was 








significantly increased (p < 0.05, Figure 4.2.A), further demonstrating the sufficiency of 
the ‘T’ allele to enhance promoter activity. Similarly, when the rs35705950 variant was 
converted to the wild type (T to G), MUC5B promoter activity was significantly 
decreased (p < 0.01, Figure 4.2.B); again demonstrating the effect of the ‘T’ allele. Taken 
together, these results demonstrate that rs35705950 is sufficient to regulate enhancer 
activity.  
Lastly, 4 of the constructs and their mutated pairs were replicated in an 
additional lung cancer cell line LC-2/ad. This replication contained the added 
perspective of an internal Renilla control. All of the constructs showed the expected 
relationship between promoter activity and rs35705950 (Figure 4.3) (p < 0.005). 
Additionally, the pooled analysis comparing the variant to the wildtype samples (both 
natural and SDM constructs) showed a significant increase in promoter activity in the 
variant constructs (p = 6.0 x 10-11). 
Figure 4.2 Site Directed Mutagenesis of rs35705950# 
A. When the variant site was converted from GG to TT, MUC5B promoter activity was significantly 
increased (n=5). B. When the SNP was converted from TT to GG, MUC5B promoter activity was 
























Distribution of MUC5B in IPF Patients 
To test our second hypothesis that the MUC5B promoter variant rs35705950 
alters the distribution of MUC5B in IPF lung, we performed quantitative 
histopathological analysis of IPF lung tissue using surgical samples obtained from the 
same subjects included in the promoter assays. We found that the percentage of fibrosis 
correlated positively and significantly with honeycomb cyst lumen, and correlated 
negatively and significantly with alveolar areas. In addition, there were no differences 
in morphometric counts for each lung structure between the GG and TT groups, 
including the epithelium of cystic structures (honeycomb cysts and alveolar cysts). 
Figure 4.3 Site Directed Mutagenesis Replication in LC-2/ad cells 
The 4 tested promoter constructs (solid colors) and their paired mutants (checkered pattern) all 
replicated the previous finding that the T allele is associated with increased promoter activity; red, 
p=0.0012; orange p = 0.00084; blue p = 0.0022; green p= 0.0023. Additionally, all of the T constructs 
had higher expression than the G constructs (p= 6.0 x 10-11) 
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These findings confirmed the presence of IPF and that the interrogated tissues 
demonstrated similar disease involvement. 
 
 
By contrast, the percentage of MUC5B positive area in the epithelial cells of 
structurally intact bronchioles from the TT samples was significantly higher than that of 
GG samples (p < 0.05) (Figure 4.4 A and B). Furthermore, the percentage of MUC5B 
positive area in the epithelial cells of the bronchiole was strongly correlated with the 
MUC5B promoter activity (r = 0.78, p = 0.005) (Figure 4.4 C). To further understand the 
influence of rs35705950 on MUC5B expression in the peripheral airway, we examined 
Figure 4.4 Immunohistochemical Staining of MUC5B in IPF Lung Tissue in Small Airways#  
MUC5B in the small airway epithelium was expressed more abundantly in the TT (p<0.05) and GT 
(p<0.005) groups than the GG group.  A/B. Data are representative of mean ± SEM (n=5, 6). A one-
tailed unpaired t-test was used. C. MUC5B promoter activity and percentage of MUC5B positive area of 
the small airway epithelium in IPF lung was significantly correlated. ● = GG samples and ○ = TT 





the distribution of MUC5B in GT heterozygotes and found that, similar to subjects with 
the TT genotypes, the GT heterozygotes have significantly more MUC5B positive 
staining in the epithelial cells of the bronchioles when compared to lung samples from 
GG subjects (p < 0.005) (Figure 4.4 B). Collectively, these findings indicate that the 
presence of the MUC5B promoter variant rs35705950 contributes to specific MUC5B 
protein expression in epithelial cells within the bronchioles in the IPF lung. 
Discussion 
 Validating the importance of rs35705950 in enhancer activity and MUC5B 
expression is an important next step in defining the regulatory architecture for MUC5B. 
Although the components of the transcriptional complex have yet to be resolved, we 
can definitively say that at least part of the complex interacts with rs35705950 in a 
dynamic and purposeful way. Additionally, the plasmid construct has allowed us to 
analyze the effect of the polymorphism on enhancer activity outside of any inherent 
chromatin structure suggesting that the effects of rs35705950 are at least in part 
independent of the surrounding chromatin. Although site directed mutagenesis was not 
conducted on the other variants identified in the MUC5B promoters of these 12 samples, 
the correlation between each variant and enhancer activity was analyzed. None of the 
other variants correlated with changes in enhancer activity; however, the plasmid 
construct provides a quick and easy way to look at the effect of novel genetic variation 
across the promoter independent of rs35705950 as well as interaction models. 
Additionally, we further validated the importance of MUC5B expression in the 
bronchiolar epithelium of the IPF lung and show that the level of bronchiolar MUC5B is 
associated with rs35705950. 
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The validation of rs35705950 as a causal variant in dysregulation of MUC5B 
expression is critical for the understanding of MUC5B regulation. Not only does this 
indicate a point of regulation but it also highlights a region where additional 
components of the transcriptional complex may bind. Knowing that rs35705950 is 




FOXA2 IS A COMPONENT OF THE MUC5B TRANSCRIPTIONAL COMPLEX 
Introduction 
 Proteomics [304], epigenomics [113, 233, 296], and genetics [19, 49] have begun 
to define the etiology of IPF and have provided insight into the development, 
progression and potential treatment of IPF. GWAS and linkage analysis have identified 
several genes that increase risk of IPF however further work in necessary to determine 
not only how these genes contribute to IPF biologically but also how the genetic 
mutations themselves affect the function of the genes or in the case of rs35705950 how 
the mutation affects expression. The characterization of these critical regions will 
provide addition tools for the manipulation of gene expression and function and will 
ultimately lead to novel options for IPF treatment and prevention.  
Background 
 Dysregulation of MUC5B expression has been noted in several pulmonary 
diseases, cancers, and diseases of the ear, reproductive tract, nasal passage and 
digestive tract. Over the last 20 years, researchers have identified several stimuli that 
are correlated with changes in MUC5B expression in in vivo models.  In mouse models, 
exposure to Pseudomonas aeruginosa pyocyanin [305] and in utero exposure to arsenic 
[306] are associated with increased expression of MUC5B. In Pigs, infection with 
actinobacillus pleuropneumoniae is associated with increased expression of MUC5B 
[307]. In human studies, cigarette smoke exposure is associated with increased 
prevalence of MUC5B in alveolar macrophages [308]. The common string through these 
exposures is the role of the immune response in activation of MUC5B expression. 
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 Several in vitro models have also looked at the regulation of MUC5B expression. 
In vitro models of MUC5B expression focused on primary normal human bronchial 
epithelial cells as well as H292, Calu-3 and A549 lung cancer cell lines. Not surprisingly, 
many immune stimulants were found to increase MUC5B expression including visfatin 
(proinflammatory adipocytokine) [309], lipopolysaccharide [310], IL-13[311],  
adenosine monophosphate-activated protein kinase[312], monocyte chemotactic 
protein 1 [313], IL-8[314], prostaglandin[315], and staphylococcus enterotoxin A [316]. 
Neuregulin 1beta1 [156], leptin [317], cigarette smoke exposure, and reactive oxygen 
species are also associated with increased expression of MUC5B in vitro [318]. 
Interestingly, culturing cells on fibronectin or laminin also increases the expression of 
MUC5B [157]. Lastly, epigallocatechin-3-gallate, a major component of  green tea 
extract, inhibits the stimulation of MUC5B expression [319] and TGF-β(2) reportedly 
decreased MUC5B expression [311].  
 The MAPK signaling pathway has also been associated with MUC5B regulation. 
The components of this pathway that have been specifically implicated in MUC5B 
regulation include p38 MAPK, ERK, NF-κB, MMP-9, ROS, RSK1, CREB, IL-1β, and IL-17A 
[157, 305, 309, 312, 315-317, 319-321]. This pathway is undoubtedly contributing to 
the regulation/dysregulation of MUC5B, likely acting through a proximal promoter 
[322]. 
The MUC5B promoter variant is associated with MUC5B expression in non-
fibrotic and IPF lung and is sufficient to alter promoter activity in vitro; however, the 
mechanism underlying this association remains unclear [19, 285]. Motif mapping 
software shows that the MUC5B promoter variant rs35705950 disrupts an E2F binding 
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site and creates both HOX9 (HOXA9-Meis1 heterodimer) and PAX2 sites. We also know 
that rs35705950 disrupts a CpG motif (CpG -> CpT) and is associated with changes in 
regional DNA methylation. Interestingly, one study determined that global DNA 
demethylation through 5-aza-2′-deoxycytidine treatment enhances gastric cancer cell 
expression of MUC5B [121] further suggesting a potential role for DNA methylation in 
MUC5B regulation. The area surrounding the MUC5B promoter variant has additional 
characteristics of an enhancer including a CpG island [323], H3K27 acetylation histone 
marks, a DNase I hypersensitivity site marking open chromatin, and occupancy of a 
histone modifier (P300)[117, 324-326].  Furthermore, 19 transcription factors have 
ENCODE reported ChIP-seq peaks across rs35705950.   
Given the location of the variant and the chromatin structure of that region, we 
hypothesized that transcription factor binding at this locus plays a role in MUC5B 
regulation. I focused specifically on transcription factors which were known to bind in 
the overlapping DMR region I previously identified.  
Methods 
Human Samples  
Human lung tissue derived RNA and DNA were obtained from the National Heart 
Lung and Blood Institute-Lung Tissue Research Consortium (NHLBI-LTRC) and 
National Jewish Health-Interstitial Lung Disease Program, including IPF (N=203) and 
non-fibrotic control (N=139) samples. Control tissue was obtained from transplant 
specimens that failed regional lung selection (NJH) or biopsies of normal tissue 
surrounding peripheral lung lesions (LTRC).  The diagnosis of IPF was determined by a 
pathology core consisting of 2 pulmonary pathologists, a radiology core consisting of 3 
68 
 
pulmonary radiologists, and a clinical core consisting of 5 pulmonary physicians. All 
diagnoses were made in accordance with established criteria [10, 212].  
Primary Cell Culture  
Normal human tracheobronchial epithelial cells were obtained from the tracheas 
of de-identified organ donors whose lungs did not meet the criteria for transplantation 
[327, 328]. The Institutional Review Board (IRB) at National Jewish Health approved 
the collection and the use of these cells.  
Primary cells (5x105 starting number) were split on to 5-collagen coated 6cm 
dishes (Corning, 356401) and grown to confluency in BEBM media with all of the 
additives from the Lonza SingleQuot ALI supplement kit (Lonza, CC-3170) at 37  ̊C and 
5% CO2. Primary cell culturing method summarized in Appendix B. To support the 
growth of the primary cells on the 12mm, 0.4μm pore, polyester transwell membranes 
(Corning, 3460), they were coated with PureCol bovine collagen (Advanced BioMatrix, 
5005-100ML). See extended collagen coating protocol in Appendix C. The primary cells 
were transferred to the transwell membranes, grown to confluency and moved to an 
air-liquid interface (ALI). Cells were maintained at ALI for 2-3 weeks (Protocol in 
Appendix D). 
Cancer Cell Line Selection 
 RNA from 30 lung cancer and colon cancer cell lines were screened for MUC5B 
expression, as well as, expression of the 24 transcription factors predicted to bind in the 
MUC5B promoter. Additionally, DNA from these cell lines was harvested and DNA 




Genotyping and Expression 
Whole lung (Qiagen DNeasy, Valencia, CA) and peripheral blood DNA (Qiagen 
PAXgene blood kits, Valencia, CA) were used to genotype each individual for 
rs35705950 using a pre-validated assay [19]. Total RNA isolated from lung tissue of the 
cases and controls was reverse transcribed using SuperScript III reverse transcription 
kits (Invitrogen, Grand Island, NY) according to the manufacturer’s protocol. MUC5B 
expression levels were determined using a pre-validated MUC5B (Hs00861588_m1) 
Taqman gene expression assay (Applied Biosystems, Foster City, CA) and normalized to 
the pre-validated GAPDH (Hs99999905_g1) assay [19]. Relative gene expression data were determined and analyzed using the ∆∆Ct method [213] and two-tailed t tests for 
significance. 
ChIP-qPCR 
Cancer Cell ChIP: A549 and LC-2/ad cells were chosen for ChIP given the 
abundance of knowledge available for A549s and the high expression of MUC5B in LC-
2/ad cells.  Each cell line was grown to 100% confluency under standard conditions. 
ChIP was performed as previously described [329] with minor modifications. 
Crosslinking was performed for 3 and 5 minutes for A549 and LC-2/ads respectively. 
Fragmentation was conducted at 24 and 30 cycles (1 cycle = 30s sonication, 30s 
cooling) for the A549 and LC-2/ad cell lines respectively in a Diagenode Bioruptor. Pull-
down was performed using RNA polymerase II (Covance-MMS-126R) and FOXA2 (Santa 
Cruz sc-6554-x) antibodies.  
Primary Cell ChIP: Primary tracheal cells were provided by Dr. Chu at National 
Jewish Health. These de-identified primary human trachea cells were cultured at ALI 
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(air liquid interface) as previously described [328] and harvest after 10 days at ALI for 
ChIP. Primary cells were crosslinked and fragmented as above with 35 cycles of 
shearing.  ChIP was performed as in the cancer cells above. 
qPCR: After ChIP, the enriched DNA was quantified by qPCR. The Ct values for 
each site were compared to the Ct value calculated by the geometric mean of 2-3 
negative control regions. Statistical analysis was a standard two-tailed t-test. All ChIPs 
were performed in biological quadruplicate. The qPCR primer list is in Table 5.1. 
 
FOXA2 Mutant Reporter Assay 
The MUC5B promoter reporter construct [285] was mutated to disrupt the 
conserved FOXA2 binding motif using the Agilent Quikchange II Site-Directed 
Mutagenesis kit. The specific mutations were selected because of a prior observation 
that a plasmid carrying that haplotype had low reporter activity. Cancer cells (A549 and 
H358) were transfected with the reporter plasmid, SV40-Renilla and mCherry at a ratio 
of 10:1:1 using Lipofectamine 2000 (Thermo Fisher Scientific). The A549 and H358 cell 
lines were selected for this assay given the relative abundance of MUC5B expression 
and transfection efficiency.  After 24 hours, luciferase activity was assayed using the 
Table 5.1 qPCR Primers for ChIP 
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Promega Dual Luciferase Reporter assay and luciferin levels were normalized to Renilla 
levels.    
siRNA Knock Down 
 Dharmafect smartpools were used to knockdown the tested transcription factors 
(positive control, Cyclophilin B, D-001820-01-50; negative control, non-targeting, D-
001810-10-20; FOXA2, L-010089-00-0010). Suggested transfection reagent, concentrations and volumes were used for A549s (96 well format, 0.2 μl Dharmafect 1 and 0.5μl of 5μM siRNA per well, harvested 24 hours post transfection). For H2122 
0.5μL of Dharmafect1 and 0.5μl of 5μM siRNA were used for transfected and cells were 
harvested 48 hours after transfection. For LC-2/ad cells 0.2μL of Dharmafect1 and 0.2μl 
of 5μM siRNA were used for transfected and cells were harvested 24 hours after 
transfection. H358 cells were transfected with 0.5μl Dharmafect1 and 0.5μl of 5μM 
siRNA and cells were harvested 24 hours after transfection 
Results 
Cell Line Characterization 
 Twenty-nine cell lines were characterized to determine which cell lines would 
provide the most benefit in future experiments. The majority of the tested cell lines 
originated from the lung; LC-2/ad, H1993, H358, H2122, H2228, H3122, H727, H1650, 
A549, H2347, H1155, Calu3, SW1573, H23, Calu6, H460, H2009, HCC44, H1734, H1792, 
HCT-116 and H520. The analysis also included 1 glioblastoma cell line (U118MG) and 6 
gastric and colon cancer lines (LS174T, KM12, Kato III, HT-29, HCT-15, and H157). 
These cells were chosen given the observation that lung, colon and brain tumors have 
been reported to have increased expression of MUC5B (Appendix E1).  
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 Only three of the cell lines carried the variant at rs35705950; H1993, GT; HCT-
116, GT; Calu6, TT. The MUC5B promoter polymorphism was not associated with 
expression of MUC5B in the lung cancer cell lines, likely because of the small number of 
samples and diversity of the cell and cancer types. Additionally, expression of the 24 
transcription factors predicted to bind in the overlapping DMR was assayed in all 29 of 
the cell lines (Appendix E2). Lastly, DNA methylation of the overlapping DMR was 
assayed using pyrosequencing. Methylation of the overlapping DMR was highly variable 
between cell lines as well as between CpGs within a single cell line. There is no 
correlation between expression of any of the transcription factors or DNA methylation 
and MUC5B expression across cell lines. 
 Identification of a Critical Regulatory Domain for MUC5B 
Having identified a region of differential methylation associated with IPF, 
MUC5B expression and the variant, we next applied conservation analysis as a tool to 
identify potential regulatory sites within this region.  In the 1000 Genomes Project only 
3 variants were identified within the overlapping DMR and these variants were found in 
less than 1% of the population (Chr11:1241281, 0.137%; Chr11:1241329, 0.137%; 
Chr11:1241361, 0.458%). Cross-species analysis indicated that the wild type G allele at 
rs35705950 is the major allele in primates including gorilla and gibbon (Figure 5.1). 
Thirty-two base pairs downstream of rs35705950 is a highly conserved region   
(Chr11:1241262-1241269) containing a FOXA2 binding site (Chr11:1241254-
1241270) that is also conserved in the gorilla and gibbon as well as other mammals 
including the kangaroo rat, the Damara mole-rat, and the mouse (Figure 5.1). 






Figure 5.1 Motif Conservation  
The wildtype allele at rs35705950 is conserved in higher order apes as well as lower order monkeys; however the thymine is the wildtype 
allele in other mammals including polar bears and mice. Downstream from rs35705950 is a highly conserved string of base pairs which is 
100% conserved from the human sequence to the buffalo and the Damara mole-rat. This region includes the critical binding domain for the 




(Chr11:1241254-1241270) in the 1000 genomes project further suggesting the 
evolutionary importance of this region. 
 To determine whether the FOXA2 binding site contributes to transcriptional 
regulation of MUC5B, we disrupted the conserved FOXA2 motif (Figure 5.2.A) within a 
MUC5B promoter reporter that we described previously[285](Plasmid Map in Appendix 
F). Congruent with our prior findings, the parent construct with an intact FOXA2 motif 
generates significant luciferase activity [285], however, when the conserved FOXA2 site 
is disrupted,  luciferase activity is markedly decreased (H358 cells, p = 1.7 x 10-8; A549 
cells, p = 5.9 x 10-9) (Figure 5.2.B), suggesting a critical role for this highly conserved 
FOXA2 site in regulating Muc5B expression. 
FOXA2 and RNA Polymerase II ChIP  
FOXA2 binding at the predicted motif (Figure 5.3.A) was assayed using ChIP-
qPCR in the pulmonary adenocarcinoma cell line, LC-2/ad, which expresses high levels 
of MUC5B. In LC-2/ad cells, FOXA2 occupies the enhancer region with a 201-fold 
enrichment over background (p = 1.6 x 10-9) (Figure 5.3.B).  Next, enrichment of RNA 
polymerase II occupancy was assayed firstly at the TSS to verify the transcriptional 
activity of MUC5B and secondly at the enhancer as a predictive measure of enhancer 
activity [112] . RNA polymerase II showed a 15-fold enrichment (p = 0.015) at the TSS 
and a 14-fold enrichment of occupancy (p = 0.0009) at the enhancer (Figure 5.3.C). In 
aggregate, these findings indicate that MUC5B is actively transcribed in LC-2/ad cells, 
and also suggests that the 4kb promoter variant is located within an active enhancer. 
Similar results were observed in an additional lung cancer cell line A549 (Figure 5.4). 
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FOXA2 Binding in the MUC5B Promoter in Primary Cultures 
Primary human tracheal cells do not produce MUC5B in submerged conditions 
but when cultured at air liquid interface (ALI) they differentiate into mucosal and 
ciliated cells that produce high levels of MUC5B [330]. This provides a dynamic model 
for studying transcriptional control of MUC5B. Primary human tracheal cells were 
grown to confluence and either harvested in a submerged state or moved to ALI and 
then harvested for ChIP-qPCR.  First, we used RNA polymerase II ChIP-qPCR to validate 
that the ALI culture resulted in increased transcriptional activity compared to 
submerged cells (Figure 5.5). Interestingly, the submerged cultures maintain binding of 
RNA polymerase II at the enhancer site, perhaps suggesting that the transcriptional 
complex is primed but requires additional signals to initiate transcription.  
Occupancy of FOXA2 at the predicted enhancer was assayed in both the 
submerged and ALI culture conditions. As expected, the ALI cultures show robust 
occupancy of FOXA2 at the enhancer site (Figure 5.6) (62-fold, p = 5.1 x 10-12). 
Interestingly, the submerged cultures also have binding of FOXA2 at the enhancer site 
(12-fold, p = 1.3 x 10-9), however, the ALI cultures have a 5.1 fold higher occupancy (p = 
1.9 x 10-8) compared to the submerged cultures indicating that binding of FOXA2 is 
dynamically associated with MUC5B expression. 
FOXA2 Affects MUC5B Expression 
There are 24 transcription factors that have either conserved binding motifs or 
validated binding through ChIP-Seq [326] within the overlapping DMR. To determine 





Figure 5.2 FOXA2 Binding Site is Critical for Promoter Activity 
 A. The FOXA2 binding motif in the MUC5B promoter construct was disrupted using site directed 
mutagenesis. A “CT” insert, “AAA”  “C” in/del and a “C”  “T” point mutation were made.  B. The 
MUC5B promoter construct clones show that the 4.2kb region directly upstream of the MUC5B 
transcriptional start site has promoter activity as see as relative luciferase of the WT constructs 
(blue) (pGL4.10 with MUC5B promoter insert) over the empty vector (black) (pGL4.10 with no 
insertions). After site directed mutagenesis of the conserved FOXA2 motif in the WT reporter, the 
FOXA2-mutant reporter clones (yellow) shows a significant decrease in promoter activity (H358 data 







Figure 5.3 ChIP-qPCR Occupancy of FOXA2 and RNA Polymerase II in LC-2/ad Cancer Cells 
A. The two regions targeted by qPCR were at the predicted enhancer site (red) and the MUC5B TSS 
(blue). B. FOXA2 shows high occupancy at the predicted enhancer with a 201-fold enrichment (p = 
1.6 x 10
-9
). C. RNA polymerase II (Pol2) occupancy is enriched for at the TSS (15-fold, p=0.015) 
indicated that MUC5B is being actively transcribed. Additionally, Pol2 is enriched for at the enhancer 
increasing the likelihood that this is an active enhancer motif (14 fold, p=0.0009). Two-tailed t tests 








    
 
Figure 5.4 ChIP-qPCR Occupancy of FOXA2 and RNA Polymerase II in A549 Cells  
The positive control (green), enhancer (red) and MUC5B TSS (blue) qPCR data is graphed with fold 
change indicated above each bar. A. Relative occupancy of FOXA2 at the enhancer indicates binding of 
FOXA2 with high relative occupancy. B. RNA polymerase II occupancy is enriched for at the TSS as 
well as the enhancer, indicating that MUC5B is being actively transcribed and increases the likelihood 





   
 
Figure 5.5 RNA Polymerase II Occupancy in ALI and Submerged Cultures  
There is a 5.1 fold (p = 0.0004) enrichment of occupancy of RNA polymerase II (Pol2) at the 
MUC5B transcriptional start site (blue) in the ALI cultures (A) while the submerged cultures (B) 
do not show enrichment of occupancy (-1.5 fold enrichment, ns). This suggests that the 
submerged cultures are not transcriptionally active while the ALI cultures are. The Pol2 positive 








Figure 5.6 Primary Tracheal Cell FOXA2 ChIP-qPCR 
Binding of FOXA2 to the enhancer was assayed in undifferentiated submerged cultures (B) and 
differentiated ALI cultures (A). There is increased occupancy of FOXA2 at both the submerged (62-
fold, p = 5.1 x 10-12) and ALI cultures (12-fold, p = 1.3 x 10-9). The relative occupancy of FOXA2 at the 
enhancer was increased by 5.1-fold (p = 1.9 x 10-8) in the MUC5B expressing ALI cultures compared 



























































































components of the transcriptional complex, siRNA knock down of the 24 transcription 
factors was completed in A549s, a lung carcinoma cell line which expresses moderate 
levels of MUC5B. Of the tested transcription factors 4 had a significant effect on MUC5B 
expression. FOXA2 (26.8-fold decrease, p = 0.001) had the strongest effect on MUC5B 
expression (Figure 5.7). Knockdown of STAT3 (16.3-fold decrease, p = 0.002), HOXA9 
(17.6-fold, p = 0.002) and ZBTB7A (12.0-fold decrease, p = 0.002) also decreased 
MUC5B expression. Interestingly, the T allele at rs35705950 creates a de novo putative 
HOXA9-MEIS1 binding site and STAT3 has been shown to regulate FOXA2 [331]. The 
siRNA KD of FOXA2 has been replicated in 3 additional cell lines (H358, LC-2/ad and 
H2122) each showing significant down regulation of MUC5B. 
Figure 5.7 Effects of siRNA Knockdown of Transcription Factors on MUC5B Expression 
 A total of 24 transcription factors predicted to have binding near rs35705950 were knocked down 
using siRNA and the effect on MUC5B expression was measured using qPCR. Fold change in MUC5B 
expression was calculated using the ∆∆CT method and significance was calculated using a standard t 
test with a corrected p value of significance of 0.0021.  Four transcription factors significantly down 






Our study identifies a critical regulatory domain in the MUC5B promoter that can 
be modulated by the MUC5B promoter variant rs35705950, DNA methylation, and 
binding of FOXA2. Interestingly, FOXA2 is known to play a key role in early lung 
development and lung homeostasis [332]. Furthermore, identification of FOXA2 as a 
necessary component of the MUC5B transcriptional complex and isolation of the 
relevant binding regions provide us with the necessary tools to identify additional 
factors that contribute to regulation of MUC5B.  
Although the previously identified MUC5B promoter variant rs35705950 is 32 
bp upstream from the FOXA2 binding motif, it is likely that the variant and the binding 
site function together within a composite regulatory element. There are two probable 
hypotheses for the interaction between these two sites. First, the MUC5B promoter 
variant is associated with regional changes in methylation surrounding the FOXA2 
binding motif and this could directly affect FOXA2 occupancy. In this case, we would 
hypothesize that increased methylation of the surrounding area leads to increased 
binding of FOXA2. Alternatively, the MUC5B promoter variant may alter the binding 
affinity/specificity for other transcription factors that interact with or are recruited by 
FOXA2 to regulate MUC5B expression. In that regard, our data indicate that knockdown 
of HOXA9, which is predicted to preferentially bind the promoter variant, leads to 
decreased expression of MUC5B. Intriguingly, the HOX and FOX family of proteins are 
already known to cooperate in gene regulation [333, 334].  Moreover, activation of 
STAT3 is associated with down regulation of FOXA2 [331] and here we show that knock 
down of STAT3 reduces the expression of MUC5B.  
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Interestingly, the identification of FOXA2 at a regulatory of MUC5B expression 
may also explain a discrepancy between previous methylation data by Vincent et al. 
[121] which suggested a negative association between DNA methylation and MUC5B 
expression and my data which indicates a positive association. In Vincent’s work 
treatment with the global DNA demethylating agent 5-azacytidine lead to an increased 
expression of MUC5B. However, Barah Halpern et al. show that DNA demethylation 
activates FOXA2 gene expression [335]. These two findings in addition to my work may 
suggest that global DNA demethylation may activate FOXA2 and the activation of FOXA2 
upregulates MUC5B expression. Further work needs to be done to resolve the role of 
DNA methylation in transcription factor binding and MUC5B regulation.  
Defining a MUC5B enhancer and identifying FOXA2 as a critical regulator 
establishes a rationale for pharmacologic targeting of FOXA2 to reduce the expression 
of MUC5B in IPF. Our work also provides a framework to define additional transcription 
factors such as HOXA9, STAT3 and ZBTB7A that increase MUC5B expression. The 
dysregulation of MUC5B appears to be of importance not only to the roughly 60% of IPF 
patients with the variant but IPF as a whole given that MUC5B appears to be 
upregulated regardless of the genotype. Our findings also add to the growing body of 
evidence linking non-coding variants to regulation of gene expression in lung disease 
and highlight the importance of integrating genetic and epigenetic variation to uncover 
novel pathways that are disrupted in lung disease. Understanding the biological 
mechanisms underlying the association between GWAS variants and disease is a critical 
next step for the elucidation of critical pathways, identification of targetable 
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components within those pathways and ultimately creation of treatments and cures for 




CHAPTER VI  
SUMMARY AND FUTURE DIRECTIONS 
Summary 
The goal of my thesis work was to define the molecular function of the MUC5B 
variant and to clarify the mechanisms responsible for MUC5B regulation. To address my 
main thesis goal I first focused on determining if the IPF variant was a unique risk 
factor for IPF. Next I looked at the association between rs35705950 and MUC5B 
expression and promoter function. Additionally, I mapped the methylome of the MUC5B 
promoter and looked at associations between DNA methylation and rs35705950, 
MUC5B expression and IPF. Lastly, I focused on identifying and validating 
transcriptional regulators of MUC5B.   
Although rs35705950 was first found to be associated with IPF many fibrotic 
lung diseases share common features and environmental risk factors and may also 
share genetic risk factors. I hypothesized that rs35705950 may also be associated with 
increased risk of other forms of ILD. I genotyped and analyzed the prevalence of the risk 
allele in our IPF, HP, iNSIP, RB-ILD and COPD cohorts. The MUC5B promoter variant was 
enriched for in the IPF and iNSIP cohorts. Interestingly, IPF and iNSIP are known to 
coexist in a single individual and are not uncommonly found in related individuals. 
Additionally, a small cohort study has shown that iNSIP can evolve into IPF suggesting a 
deeper connection between these two pathologies. The numbers were small in the HP 
and RB-ILD cohorts and further analysis is necessary. The shared genetic predisposition 
between IPF and iNSIP suggests shared disease mechanisms. 
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MUC5B dysregulation in IPF has now been noted in a number of studies. Here I 
show that in both the IPF and control groups rs35705950 is associated with increased 
expression of MUC5B. Additionally, MUC5B expression was also higher in IPF lung 
compared to control lung even after correction for rs35705950. Although additional 
covariates were added into the model (age, gender and smoke exposure), none were 
found to be associated with MUC5B expression. Furthermore, rs35705950 was proven 
to have a causal relationship with MUC5B dysregulation through reporter assays. These 
assays indicate a robust and reproducible effect of the variant in a number of MUC5B 
promoters with additional genetic variation.  
DNA methylation patterns in the MUC5B promoter were of interest given that 
the MUC5B promoter variant disrupts a CpG motif within a CpG island and previous 
work shows that there are genome-wide changes in the IPF methylome. Using a 
targeted approach I was able to identify differentially methylated regions within the 
MUC5B promoter that are associated with rs35705950, IPF and MUC5B expression. 
Interestingly, all of the risk variables—T allele, IPF and high MUC5B expression—were 
all associated with increased methylation of the CpGs surrounding the variant. Although 
this analysis does not address whether the changes are the result or the consequence of 
these variables, it does help us highlight a potential regulatory region.  This overlapping 
DMR region contains a differentially methylated CpG island, histone modifications and 
modifiers, binding of almost 20 transcription factors and a region of deep conservation. 
Within the overlapping differentially methylated region, which includes 
rs35705950, there are 19 predicted transcription factor binding sites. These site were 
identified through the ENCODE ChIP-Seq project and through motif mapping. Although 
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these methods provided a large number of potential regulators, neither is all 
encompassing. Many of the Chip-seq hits do not have conserved binding motifs within 
them and only 121 transcription factors have been added to the ChIP-Seq database. 
Additionally, the ChIP-Seq data from the ENCODE project comes from mostly cancer cell 
lines, many with treatments and few that have been validated in more than 1 cell lines. I 
was able to focus my search down to a handful of interesting transcription factors by 
knocking down all 24 of the predicted transcription factors with siRNAs. This 
highlighted 4 transcription factors which when knocked down altered MUC5B 
expression; FOXA2, STAT3, HOXA9 and ZBTB7A. Of the identified transcription factors 
FOXA2 was particularly interesting given previous findings which loosely associated 
FOXA2 with regulation of mucins. Additionally, the FOXA2 motif is highly conserved 
across species and shows the greatest occupancy of the tested transcription factors 
from the ENCODE project. 
To determine if FOXA2 was playing a direct or indirect role in regulation of 
MUC5B I asked two main questions; first, does FOXA2 bind to the predicted motif in a 
cell type that expression MUC5B and second if we disrupt that site is promoter activity 
affected. To answer the first question, ChIP-qPCR was done in A549 and LC-2/ad lung 
cancer cell lines and normal human tracheal primary cells. In all of the cells, FOXA2 
robustly occupies the promoter. RNA polymerase II also binds to the promoter, further 
suggesting that this region is regulatory and active [112]. Next, I mutated the FOXA2 
motif in a MUC5B promoter reporter construct. The mutated constructs were no longer 
predicted to bind FOXA2 through motif analysis and there was a dramatic decrease in 
promoter activity. Together with the siRNA data I have demonstrated that FOXA2 binds 
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in this region, that this region is critical for promoter activity, and that FOXA2 affects 
MUC5B expression.   
The deep conservation of this region is perhaps the most concrete evidence that 
this region is important. The 1000 Genome’s Project did not identify any SNPs within 
the FOXA2 binding motif and the critical domain of the FOXA2 motif has 100% 
conservation in all of the species that we looked at including species such as the mole 
rat and the polar bear. This finding suggests strong evolutionary pressures to maintain 
this sequence. Interestingly, there is also strong conservation of rs35705950 in 
primates but the T allele is more common in non-primate species. Together these data 
could suggest that regulation of MUC5B—if we correcting in thinking that this is the 
main function of this region—is critical for normal function of the lungs or other mucus 
coated organs but that very early on in the evolution of primates having less MUC5B 
was favorable. Similarly, this could also suggest Caucasian specific pressures to increase 
the amount of MUC5B expression. Given what we now know about the function of 
MUC5B in the lung, it is possible that increased mucin may have aided in the immune 
response to a specific pathogen or helped to protect from an exposure unique in 
Europe. Conversely, perhaps the early Homo sapiens which migrated to Europe were no 
longer exposed to the selective pressure which preserved the G allele at rs35705950.  
It is also conceivable that the pressures related to the expansion of the T variant 
in the Caucasian population had nothing to do with lung health. MUC5B is also 
expressed in the digestive tracts, upper respiratory tract and in the reproductive tract. 
Perhaps the additional reproductive tract mucus was advantageous to conception at an 
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evolutionary period when Homo sapiens migrated to Europe.  Similarly, increased 
mucus in the digestive tract may have aided in the digestion of foods native to Europe.  
Understanding the regulation of MUC5B could lead to interventions that alter 
regulation and alter disease progression in a number of pulmonary and non-pulmonary 
conditions. MUC5B is dysregulated in IPF as well as other pulmonary diseases including 
asthma[336], diffuse pan bronchiolitis[151], and coal workers pneumoconiosis [152]. 
Although MUC5B is a secreted protein and could more readily be targeted at the protein 
level where the intervention would not necessary have to cross the cell membrane, 
targeting of the protein may be too far downstream. Early results in the lab suggests 
that over production of MUC5B leads to endoplasmic reticulum (ER) stress and this 
could be contributing to the lung remodeling we observe in IPF. Optimally, therapeutic 
intervention for MUC5B will involve targeting of transcription and protein. 
Understanding how MUC5B is regulated and how it becomes dysregulated could lead to 
a deeper understanding of the mechanisms underlying pulmonary diseases and provide 
additional targets for the regulation of MUC5B. With therapeutics targeted at the 
regulation of MUC5B it may be possible to slow or stop the progression of IPF and in 
high risk groups it may even be possible to prevent its development. Although this is a 
long way off, this thesis takes the first step in understanding the mechanisms 
underlying regulation of MUC5B expression and provides FOXA2, HOXA9, STAT3 and 
ZBTB7A as 4 potential targets.  
Future Directions 
 The structure of the MUC5B promoter and enhancer and the transcriptional 
complex require additional characterization. The role of FOXA2 in the regulation of 
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MUC5B could be further validated by dual transfection of the MUC5B promoter reporter 
construct and either a FOXA2 overexpression construct or FOXA2 siRNA. Alternatively, 
a MUC5B expressing cell line could undergo genome editing to knock out FOXA2 and 
the effect on MUC5B expression could be assayed. Additionally, HOXA9, STAT3 and 
ZBTB7A could be assayed using the same method to determine their role in MUC5B 
expression. Other components of the complex are currently being elucidated using 
synthetic pulldown methods followed by mass spectrometry identification. Although 
this method has its obvious limitations it could lead to the identification of less well 
known components of the transcriptional complex. Additionally, now that FOXA2 is a 
known component of the transcriptional complex, chromatin conformation capture 
(3C) could also be utilized to further characterize the structure of the promoter 
including looping structures. ChIP-reChIP could also be used to clarify close 
relationships between predicted components of the same complex. For example, 
chromatin would be ChIPed for FOXA2 and then HOXA9 and qPCR would be targeted at 
the enhancer site.  
 Knowing the components of the transcriptional complex and the regions of 
regulatory importance could lead to the identification of novel genetic risk factors for 
IPF which may have been missed in GWAS and linkage analyses due to low penetrance, 
small effect sizes, or rarity. Genetic risk factors can be used to better assess individual 
risk and perhaps someday may be used to optimize treatment.   For example, not all 
people with IPF have elevated expression of MUC5B and those with normal levels of 
MUC5B may therefore not benefit from mucin reduction.  
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 It is unclear if the MUC5B promoter variant affects binding of FOXA2. The 
Schwartz lab is currently continuing work that I started using the CRISPR-Cas9 system 
to create a point mutation converting the wildtype allele to the variant allele in a lung 
cancer cell line. Additional efforts should also be made to create this mutation in an 
immortalized primary cell line. Once the point mutation has been created ChIP could be 
used to determine the effects of the variant on binding of FOXA2 as well as the other 
components of the transcriptional complex to define which one(s) is affected by the 
variant. 
 Idiopathic pulmonary fibrosis is unique from most pulmonary diseases in that it 
has a 100% mortality rate. During the progression of IPF, patients suffer from 
worsening clinical phenotypes, poor quality of life and very limited treatment options. 
It is my hope that this research helps provide steps towards a treatment and perhaps 
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 APPENDIX A 
Distribution of MUC5B Promoter Methylation in IPF and Unaffected Lung 
Each graph depicts the distribution of DNA methylation at a single CpG motif. 
The data is separated into non-fibrotic control lung tissue (Control-Pink) and IPF lung 
tissue (Blue).   
 







































































Growing Normal Human Bronchial Epithelial Cells in Air-Liquid Interface 
1) Primary cells obtained from Hong Wei Chu, National Jewish Health. 
2) Once you get the frozen vials containing the cells, thaw the vial at RT ( Each vial can 
be expanded into 5 X 6cm dishes) 
3) Transfer contents of thawed vial to 5ml of cold BEGM (BEBM + required 
supplements) 
4) Centrifuge at 1000 RPM for 10min at 4oC (Pellet will be very small) 
5) Pour off supernatant immediately ( get as much as possible as freeze down solution 
contains DMSO, which is very toxic to cells) 
6) Resuspend in 1ml of warm BEGM ( then add up to 4ml of BEGM/6 cm dish) 
7) Transfer into (4-5) labelled dishes 
8) Next day, inspect cells under microscope to make sure they are doing ok 
9) Change media every other day (3ml/dish during weekdays and 4ml during 
weekends) 
10) When the cells are ~90% confluent then passage the cells 
11) Passaging protocol 
a) Wash cells with PBS 
b) Add 2ml trypsin (RT) / dish and leave the cells at RT for ~ 5min 
c) Take 2ml of TNS (Trypsin Neutralizing Solution??)/dish in to a conical tube 
d) Add the cells + trypsin to the tube and mix 
e) Rinse the dish with 1ml TNS and add to the tube 
f) Spin the cells @1000 rpm for 10min at 4oC 
g) Pour off the trypsin and resuspend in 1ml BEGM 
h) Add additional 15ml BEGM and spin them down again as above 
i) Resuspend in BEGM for counting ( volume  arbitrary) and then reseed 
12) Freezing protocol 
a) Pour off the trypsin+ TNS and resuspend in freezing media 
i) Freezing media 
600 ฀l BEGM 
300 ฀l FBS 
100 ฀l DMSO 
0.5 million cells in 1ml of freezing media / vial  
12) When in transwells, media can be vacuumed out from the bottom of the dish but 




Preparation of Collagen Coated Transwell Membrane Inserts 
 
Note:  PurCol Bovine Collagen (3mg/mL, Inamed, 5409 or Advanced BioMatrix 5005-
100ML) must be kept on ice to prevent polymerization at room temperature.  
Preparation of transwells should be conducted under a sterile biosafety hood.  
The polymerized collagen should appear evenly distributed to the naked eye and 
can be inspected further under a microscope.  Collagen granules should be 
approximately 2-3 granules apart when polymerized.  Plates should be used the 
day of coating. 
 
1. Add 0.5mL of sterile room temperature HyClone10xPBS to 4 mL of bovine 
collagen (3mg/mL). 
a. Add to 50 mL falcon tube 
b. Draw up and down with pipet-aid to mix, do not vortex 
i. Vortexing would cause solution to foam/bubble 
2. Add 30 ul of 1N NaOH. 
a. This is used to balance the pH, so the amount may be adjusted depending 
on age  
3. Mix with pipet-aid, do not vortex   
4. Add a drop of the PBS/Cell Prime onto pH paper. 
5. The cell prime should be slightly acidic, pH 6-7/the color of the ph paper. 
6. If needed, adjust the pH by adding 1N HCL or 1N NaOH. 
7. Add 160ul of the PBS/Cell Prime to the center of each transwell. 
8. In a small circular motion, shake the plate for ~10 seconds to spread the 
collagen evenly over the membrane. 
a. This can be done outside of the hood, but make sure to cover the plate 
9. Return to hood. To remove collagen, use forceps to lift out the individual wells 
a. Draw up collagen using pipet, collect the collagen solution into a new 
falcon tube.  
b. Do not add used collagen to original falcon tube, avoid mixing new 
solution with used. 
10. With the plate lid off, let the collagen dry for 1 hour at room temperature under 
a biosafety hood. 
 
Note:  One coat for human large airway cells, two coats for human small airway and 
mouse epithelial cells 
 





 Plates – CoStar 3460 Transwell Plates  
 Be very gentle when drawing up collagen, layer must be perfectly even or cell 
growth may be disrupted 
o Make sure to get rid of bubbles 
 Wells do not need to be completely dry when collagen is removed, just as dry as 
possible 
 Make sure not to cross arm over the uncovered plate 
 Close the plates after they have been drying open for one hour – keep track of time 
 Do not need to fully close the hood while plates are drying, it can be left at working 
height  
 This formula is enough to coat two plates, plus a third if collagen is collected and 
reused 
 MUST keep collagen on ice inside hood  
o It is stored in the door of the fridge in cell culture room (NaOH is nearby) 






ALI Plating and Medium Change Procedures 
 
Medium: 
BEGM w/ GA: • All SingleQuot supplements  
 
F6: • 1:1 ratio of BEBM and DMEM (high glucose with sodium pyruvate) 
o AND  Insulin, Transferrin, Hydrocortisone, Epinephrine, BPE, GA from 
SingleQuot pouch  
 
Full F6: • F6 plus  
Supplement 
Volume (per 25 mL) 
(Stock [conc]) 
Final [conc] 
Albumin bovine (Sigma, A9418-
10G) 250µl (50mg/mL) 0.5ug/mL 
Ethanolamine (Sigma, E0135-
500ML) 25µl (80mM) 50mM 
MgCl2 (Sigma) 25µl (0.3M) 3.0mM 
MgSO4 (Sigma) 25µl (0.4M) 4.0mM 
CaCl2 (Sigma) 25µl (1M) 1.0mM 
Retinoic acid (Sigma, R2625-50mg) 2.5µl (0.3µg/µL) 30ng/mL 
Human NHBE EGF (Upstate, 01-
107) 25µl (10µg/mL) 10ng/mL 
*The Retinoic Acid from the singlequots is too dilute to use. 
*F6 plus must be made up fresh each day. 
 
Expanding cells in collagen coated dishes (Fisher 0877274):  • BEGM w/ GA (4 mL/dish) 
 
Seeding cells to transwells (Sigma, CLS3460-48each): 
1. Trypsinize cells, obtain 4x104 cells/well  
a. For 4 transwells, need ~2 million cells  
2. Resuspend cells in full F6 (500 μL per top of transwell) 
3. Seed 500 μL of cell solution on top and 1.5 mL of Full F6 on bottom 
 
Day 2:  
1. Refresh medium by removing 500 μL from top of transwells 
2. Move 300 μL from bottom to top  
 
Day 3-6: 
1. Remove all medium from top, add 300 μL fresh Full F6 
151 
 
2. Remove all medium from bottom, add 1.2 mL fresh Full F6 
 
Day 7/ALI Day 1: • Or when cells have fully expanded to cover the transwells • Check around the edges carefully for holes  
 
1. Remove all medium from the top, add 50 μL of fresh Full F6 
2. Remove all medium from the bottom, add 1.2 mL of fresh Full F6 
 
Medium changes in ALI: Day 2-14  
1. Washing step: move 250 μL from bottom to top 
2. Cover and swirl plate to coat top of transwell 
3. Remove 300 μL from top 
4. Replace with 50 μL fresh Full F6 
5. Remove all medium from bottom, replace with 1.2 mL fresh Full F6 
 












Lung and Colon Cancer Screen 
A large number of lung cancers and colon cancers have been reported to express 
high levels of MUC5B. To determine which cell lines express high levels of MUC5B and 
determine which would be the best to use for experiments, 30 cell lines were grown to 
confluency and harvested for RNA and DNA. The RNA was used to screen for expression 
of MUC5B (Figure E1) and the 24 transcription factors which we predicted regulate 
MUC5B expression (Figure E2). The DNA was used to genotype the cell lines for the 
MUC5B promoter variant (Figure E1) and determine the methylation state of each cell 






LC-2/ad 17.84 GG 
H1993 16.31 GT 
H358 14.54 GG 
H2122 13.90 GG 
H2228 13.56 GG 
H3122 12.92 GG 
*LS174T 11.51 GG 
H727 10.84 GG 
*KM12 8.79 GG 
*KATO III 8.29 GG 
H1650 8.01 GG 
A549 7.81 GG 
H2347 7.25 GG 
H1155 7.05 GG 
H1155 7.05 GG 
*HT-29 4.00 GG 
Calu3 3.56 GG 
SW1573 2.27 GG 
*HCT-15 1.71 GG 
H23 1.48 GG 
Calu6 0.99 TT 
H460 0.56 GG 
H2009 ND GG 
HCC44 ND GG 
*H157 ND  GG 
H1734 ND GG 
H1792 ND GG 
HCT-116 ND GT 
H520 ND GG 
**U118MG ND GG 
 
Figure E1 MUC5B Expression 
and rs35705950 Genotype in 
Cell Lines 
Relative MUC5B expression is 
calculated as the cycle threshold (Ct) of 
MUC5B – GAPDH Ct as a delta Ct. The 
delta Ct value is then inverted so that 
higher expression of MUC5B has a 
larger number this is done by take 20 – 
delta Ct.  








Cell Line REST ESR1 NFIC TEAD4 EP300 TCF12 ELF1 CEBPD SP1 
H727 9.90 16.71 10.46 10.54 9.29 8.57 6.93 11.16 8.26 
H157 4.73 N/A 7.01 7.56 9.44 6.56 8.25 8.23 8.04 
H2228 5.35 11.32 6.38 8.19 9.35 8.30 7.55 6.54 8.27 
Calu3 4.93 17.22 8.02 8.55 7.75 6.97 6.08 8.53 8.18 
LC2/AD 4.40 13.00 5.26 8.93 6.52 6.38 4.63 3.96 5.63 
Calu6 7.13 N/A 7.98 7.07 8.31 6.03 6.43 8.74 7.86 
H1155 11.14 14.71 7.28 8.40 7.66 7.30 7.59 8.44 7.85 
H460 6.12 20.49 6.83 8.50 8.51 7.60 7.06 8.61 7.90 
H2122 6.42 13.10 6.90 8.63 8.19 7.58 6.12 7.35 7.52 
H1734 6.79 16.60 6.73 8.69 8.59 7.43 6.87 8.32 7.60 
LS174T 7.78 17.05 8.47 10.17 9.79 9.83 6.77 8.96 9.05 
H358 4.64 14.50 5.58 8.30 6.39 5.40 4.16 4.99 5.70 
H2347 6.24 16.93 6.86 8.93 8.19 9.03 6.64 6.74 7.96 
H3122 7.75 14.96 9.70 10.28 9.33 9.21 7.21 9.12 9.87 
HT-29 5.43 8.49 6.95 8.14 7.86 8.23 5.81 7.21 6.73 
HCT-15 5.34 19.53 5.93 6.96 9.17 7.14 5.93 8.65 6.49 
HCT-116 5.45 16.07 6.10 8.17 7.70 6.72 6.01 7.75 6.45 
H1650 6.61 17.95 7.57 7.43 7.62 8.99 7.74 7.48 7.78 
H1792 6.09 13.81 6.33 7.96 8.54 7.23 7.79 6.12 7.06 
HCC44 6.26 17.42 6.62 8.27 8.50 7.98 7.92 7.89 8.44 
A549 6.95 15.49 6.92 8.40 8.10 8.00 7.07 6.98 8.84 
KatoIII 6.87 13.15 7.13 7.03 8.49 7.18 6.98 8.09 7.19 
H23 6.66 16.83 6.67 8.48 8.81 7.76 7.43 8.44 7.65 
H2009 6.48 17.96 7.00 8.11 8.89 6.58 7.76 7.11 8.08 
SW1573 6.88 21.38 6.78 8.40 8.82 7.79 7.48 8.65 8.35 
H1993 5.08 10.88 7.17 8.60 7.16 7.09 5.66 5.47 5.44 
KM12 8.20 N/A 9.43 8.45 9.89 8.75 7.52 8.73 9.12 
U118MG 8.26 16.63 6.64 10.83 10.60 8.70 9.65 8.23 9.63 




Figure E2 Transcription Factor Expression in Cell Lines 
The ENCODE ChIP-Seq database and MatInspector software were used to predict transcription 
factors that may play a role in MUC5B regulation. Expression of these transcription factors (across 
the top of each table) was assayed using Taqman assays in 29 cell lines (on the right hand side of each 
table). The numbers indicate delta Ct values (Transcription Factor Ct – GAPDH Ct) except for GAPDH 
which is the internal control and is just reported as Ct. The color coding indicates relative expression; 
















H727 8.48 N/A 9.23 8.48 4.59 6.47 10.07 6.65 6.71 
H157 13.60 18.43 9.06 8.22 18.62 4.85 11.39 6.74 N/A 
H2228 6.88 N/A 10.15 6.57 7.82 5.85 9.64 7.29 16.89 
Calu3 6.57 N/A 8.59 8.57 11.43 3.89 8.25 6.49 6.52 
LC2/AD 4.60 N/A 6.86 4.96 5.95 2.49 7.95 5.24 15.78 
Calu6 12.98 19.50 8.91 6.62 5.22 5.89 13.39 6.80 17.71 
H1155 8.21 18.05 8.29 6.52 4.31 4.85 11.51 5.67 N/A 
H460 7.99 19.59 8.93 6.40 16.94 4.46 11.09 6.89 12.51 
H2122 5.74 N/A 9.58 6.03 13.90 3.70 9.29 6.45 13.95 
H1734 7.27 N/A 8.36 6.27 16.29 4.84 10.87 7.08 12.18 
LS174T 7.28 N/A 9.20 7.92 8.41 7.93 8.10 7.63 5.80 
H358 5.91 N/A 6.39 4.17 4.41 2.51 8.70 5.54 16.29 
H2347 5.42 19.50 8.28 7.35 9.31 5.85 9.77 7.41 20.39 
H3122 5.58 19.73 9.23 8.59 9.03 6.29 11.94 7.72 17.87 
HT-29 6.30 16.92 6.40 4.42 15.32 4.28 15.24 7.21 11.94 
HCT-15 6.00 N/A 7.49 6.40 14.08 4.52 8.98 6.19 7.30 
HCT-116 11.44 N/A 8.52 6.14 12.84 3.24 10.22 5.97 8.40 
H1650 10.96 17.65 9.30 5.71 17.81 4.84 14.91 7.96 17.12 
H1792 7.44 17.77 8.74 7.45 12.48 3.16 9.53 6.88 18.69 
HCC44 7.99 19.38 9.20 7.56 8.82 4.25 10.78 7.24 18.35 
A549 7.81 N/A 9.45 6.64 6.77 5.51 11.16 7.86 8.03 
KatoIII 8.87 N/A 8.10 5.43 6.39 4.64 8.28 6.51 5.97 
H23 7.97 N/A 8.74 6.33 15.79 4.40 11.06 7.40 12.67 
H2009 14.00 N/A 8.98 7.75 18.62 4.02 11.53 6.83 N/A 
SW1573 7.62 N/A 8.67 6.30 17.85 4.28 11.01 6.76 11.59 
H1993 3.38 N/A 6.79 4.40 12.87 3.44 6.17 5.51 12.89 
KM12 6.91 19.88 9.29 9.54 6.08 6.41 8.31 6.54 6.02 
U118M
G 18.77 N/A 10.81 8.70 18.33 5.86 14.73 8.04 N/A 














Cell Line ZBTB7A PAX6 GAPDH E2F1 HOXA9 PAX2 STAT3 
H727 8.45 12.44 17.63 5.78 N/A 17.47 8.92 
H157 7.62 7.81 18.09 6.47 N/A 19.86 6.98 
H2228 8.16 17.44 17.31 7.17 N/A 18.74 6.78 
Calu3 6.85 14.42 18.37 7.53 N/A 18.61 6.62 
LC2/AD 5.40 N/A 19.69 5.62 N/A 17.51 4.97 
Calu6 7.85 8.64 18.16 6.51 17.41 18.90 8.36 
H1155 7.94 8.48 18.78 4.42 13.33 11.58 6.06 
H460 7.64 8.94 18.07 6.02 18.09 17.64 8.35 
H2122 6.36 N/A 18.61 6.89 N/A N/A 7.21 
H1734 7.30 8.89 18.37 6.55 16.73 18.45 7.97 
LS174T 7.56 12.70 18.42 8.76 15.65 N/A 8.88 
H358 5.50 18.74 19.97 8.02 N/A N/A 5.54 
H2347 7.22 16.98 17.91 5.92 N/A 19.25 7.15 
H3122 8.36 N/A 17.60 8.51 N/A N/A 8.84 
HT-29 5.99 10.69 18.99 6.85 15.32 16.18 6.07 
HCT-15 5.49 8.94 18.64 5.50 16.94 16.62 7.02 
HCT-116 5.81 9.09 19.78 7.04 14.70 10.37 6.82 
H1650 7.78 12.13 17.99 5.16 17.67 15.79 6.66 
H1792 6.24 12.36 18.71 8.54 N/A N/A 7.30 
HCC44 7.21 11.17 17.96 7.20 18.38 N/A 6.91 
A549 7.71 10.21 18.08 6.59 N/A 10.37 6.02 
KatoIII 7.03 N/A 19.16 6.17 16.45 N/A 6.40 
H23 7.50 8.74 18.42 6.38 16.85 18.46 7.98 
H2009 7.58 9.28 18.33 7.27 N/A N/A 6.62 
SW1573 6.98 7.54 17.92 6.10 17.64 15.81 7.23 
H1993 4.29 6.19 20.00 4.07 13.32 N/A 5.05 
KM12 6.96 8.92 16.99 7.00 18.90 21.52 8.55 
U118MG 7.06 9.32 17.37 7.90 N/A 20.95 7.13 












  A549 Calu3 Calu6 H23 H157 H358 H460 H727 
Chr11:124139 4 37 0 33 38 43 19 22 
Chr11:124171 7 22 88 29 36 19 13 29 
Chr11:124181 0 17 0 20 15 0 7 0 
Chr11:124220 1 3 4 49 12 8 22 0 
Chr11:124255 9 7 36 29 14 18 42 16 
Chr11:124272 11     19 16 28 67 27 
Chr11:124285 19 16 24 20 24 28 57 21 
Chr11:124291 11 12 26 32 28 20 41 15 
Chr11:124319 20 9 14 30 11 4 23 9 
Chr11:124328 9 7 8 26 8 5 22 6 
Chr11:124341 7 5 10 10 11 5 16 6 
Chr11:124375 10 6 7 12 5 5 11 6 
Chr11:124399 28 7 8 6 4 3 15 1 
Chr11:124411 7 5 4 6 3 3 8 3 
 
  H1155 H1650 H1734 H1792 H2009 H2122 H2228 H3122 
Chr11:124139 6 0     4 5 14 6 
Chr11:124171 0 0     9 66 48 49 
Chr11:124181 0 0     5 14 24 14 
Chr11:124220 13 74 30   5 0 0 0 
Chr11:124255 32 25 28 39 76 37 7 11 
Chr11:124272 77 92 47 80   50 23 15 
Chr11:124285 82 77 61 100 80 52 18 11 
Chr11:124291 49 33 39 57 25 52 36 9 
Chr11:124319 32 50 16 12 13 7 8 4 
Chr11:124328 38 28 11 7 8 10 10 6 
Chr11:124341 25 16 33 12 6 15 8 4 
Chr11:124375 21 14 8 6 5 3 6 3 
Chr11:124399 33 20 10 5 2 4 8 2 





Figure E3 Methylation of the Overlapping DMR in Cancer Cell Lines 
Pyrosequencing was used to determine percent methylation at each of the CpG motifs identified as 
within the overlapping DMR. Chromosomal position is along the right hand side of each table and cell 
lines are indicated along the top of the tables. The numbers in the tables represent percent 
methylation, black boxes indicate assays that were repeated but did not amplify likely indicating SNPs 
or In/dels disrupting the primer binding.  
157 
 
  H23917 HCC4L1 HCT15 HCT116 HT29 KatoIII LS174T LC2/ad 
Chr11:124139 18 22 32 58 11 4 4   
Chr11:124171 67 79 42 95 61 16 7   
Chr11:124181 28 25 31 94 16 4 6   
Chr11:124220 11 0 11 69 39 4 2   
Chr11:124255 27 28 23 29 26 16 17 18 
Chr11:124272 34 63 27 58 38 31 39 21 
Chr11:124285 25 58 29 53 36 30 37 12 
Chr11:124291 40 55 44 31 35 20 18 20 
Chr11:124319 18 17 10 86 41 2 5 5 
Chr11:124328 10 10 10 88 25 3 7 6 
Chr11:124341 8 12 10 88 36 3 5 8 
Chr11:124375 11 6 8 9 9 4 6 4 
Chr11:124399 13 6 19 12 4 2 2 4 
Chr11:124411 5 6 16 8 2 2 3 4 
 
 
  SW1573 H520 H1993 KM12 U118MG 
Chr11:124139 63 10 10 8 8 
Chr11:124171 76 100 100 100 100 
Chr11:124181 94 34 42 27 30 
Chr11:124220 30 0 0 0 0 
Chr11:124255   18 23 18 14 
Chr11:124272   24 23 41 30 
Chr11:124285   20 20 36 27 
Chr11:124291   15 22 21 21 
Chr11:124319 26 32 15 11 18 
Chr11:124328 20 37 16 13 23 
Chr11:124341 16 28 13 12 16 
Chr11:124375 12 12 9 9 8 
Chr11:124399 12 7 5 3 5 
































































 MUC5B Reporter Construct A 4234 bp region (Chr11:1240119-1244353) was cloned from an IPF 
patient and inserted into the pGL4.10 reporter plasmid. The patient was wildtype at rs35705950. 
Above is the inserted sequence with the pGL4.10 ends underlined to denote point of insertion.  
 
